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ABSTRACT 
Despite progress in conventional cancer treatment regimes such as chemotherapy and 
radiation therapy, metastatic disease essentially remains incurable and new treatment 
alternatives are desperately needed.  Virotherapy is a relatively novel approach in cancer 
treatment. It harnesses the natural ability of oncolytic viruses to kill the cells they 
proliferate in and to spread to neighboring cells, thereby amplifying the therapeutic effect 
of the initial input dose. The use of replicating, oncolytic viruses for cancer treatment 
necessitates introduction of various genetic modifications to the viral genome, thereby 
restraining replication exclusively to tumor cells and eventually obtaining selective 
eradication of the tumor without side effects to healthy tissue. Furthermore, various 
modifications can be applied to the viral capsid in hope of gaining effective transduction 
of target tissue. In other words, the entry of viruses into tumor tissue can be augmented by 
allowing the virus to utilize non-native receptors for entry. Genetic capsid modifications  
may also help to avoid some major hurdles in systemic delivery that ultimately lead to the 
rapid clearance of the virus from the blood and virus induced toxicity.  
We evaluated the transductional efficacy of various capsid modified serotype 5 
adenoviruses in vitro in breast cancer cell lines and in fresh patient samples. An orthotopic 
breast cancer model was used to evaluate the biodistribution of capsid modified viruses in 
vivo in mice. Based on the transductional potency data of the viruses, we created a novel 
oncolytic adenovirus featuring a polylysine (pK) motif in the fiber C-terminus to allow 
binding to heparin sulphate proteoglycans in addition to primary coxsackie-adenovirus 
receptor and evaluated its oncolytic potency in vitro alongside existing replicating agents 
featuring the other previously tested capsid modifications. We concluded that capsid 
modifications result in transductional enhancement, and that enhanced transduction 
translates into more potent oncolysis in vitro.  
The efficacy of the pK modified virus was evaluated in an orthotopic breast cancer 
model with green fluorescent protein (GFP) expressing breast cancer tumors treated with 
intratumoral injections. We developed a mouse model with imageable breast cancer 
tumors growing in the left lung to test the efficacy of capsid modified viruses in a 
systemic treatment model of disseminated breast cancer. With systemic delivery of the 
viruses, we saw prolonged survival of tumor bearing mice treated with the capsid modified 
agents. Furthermore, we were able to follow the tumor growth without invasive 
procedures in both breast cancer mouse models.  
Kupffer cells (KC) are responsible for the majority of viral clearance after systemic 
viral delivery and they play a major role in adenovirus induced acute toxicity. The 
therapeutic window could possibly be widened by transiently depleting KCs, which might 
allow smaller viral input doses and diminish KC related toxicity. KC depleting agents 
were used in vivo prior to viral injections to further enhance transductional efficacy of the 
viruses. Enhanced tumor transduction was seen, but this effect was not translated into 
enhanced antitumor activity.  
Only a small proportion of cells within a tumor may possess the capacity to proliferate 
indefinately and form new tumors. These cancer initiating cells, or cancer stem cells, 
would drive tumor formation and be responsible for posttreatment relapses and metastasis. 
 
 
 
 
Therefore, we evaluated whether transcriptionally controlled replicating viruses would be 
effective in eradicating putative breast cancer stem cells, postulated to reside in the subset 
of CD44+/CD24-/LOW cells. Effective cell killing was seen in vitro and more importantly, 
significant growth reduction of tumors derived from the CD44+/CD24-/LOW cell population 
was seen in vivo.  
Genetically modified viruses feature enhanced oncolytic potency, which unfortunately 
can increase the possibility of side effects. Therefore, it would be beneficial if the 
replication of adenoviruses could be reduced with pharmacologic intervention. We studied 
the ability of chlorpromazine and apigenin to reduce adenoviral replication and replication 
associated toxicity in vitro in normal cells, ovarian cancer cells, and patient liver samples. 
Antitumor efficacy, viral replication, and liver toxicity in vivo in an ovarian cancer model 
were also evaluated. We concluded that these agents reduced adenoviral replication and 
might be useful as safety switches in case viral replication related side effects are 
encountered. 
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i.v. intravenous 
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MIP macrophage inflammatory protein 
MOI multiplicity of infection 
MoMuLV Moloney murine leukemia virus 
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REVIEW OF THE LITERATURE 
1 Introduction 
Cancer is a major public health problem accounting for more mortalities than heart disease 
in people under 85 years of age (Jemal et al. 2009). Despite progress made in reducing 
incidence and mortality due to improvements in cancer prevention, early diagnosis and 
conventional treatment methods, cancer still accounts for approximately 6.7 million deaths 
annually worldwide (Parkin et al. 2005). Approximately 10 000 cancer deaths occur 
annually in Finland (www.cancerregistry.fi). Metastatic disease remains essentially 
incurable. 
Typically carcinogenesis is a multistep process representing alterations in 
proto-oncogenes and tumor suppressor genes (TSG) that ultimately lead to tumor 
promotion. In short, cancer is a disease of the genes, which has led to the logical 
conclusion of correcting genetic defects underlying carcinogenesis or utilizing the altered 
phenotype of cancer cells to gain specific antitumor effects. Traditionally, gene therapy 
aims at replacing dysfunctional genes with functional ones or delivering genes for the 
expression of therapeutic proteins within the cell. Since a cancer cell with a malignant 
metastazising phenotype may display up to a few hundred genes with altered functions or 
expression (Kenemans et al. 2004), traditional gene therapy approaches may not be 
sufficient to gain therapeutic effects.  
Instead of correcting genetic defects, oncolytic virotherapy takes advantage of the 
similarities between requirements of carcinogenesis and DNA virus replication to direct 
the antitumor effect of an oncolytic virus to tumor. Adenoviruses are widely studied and 
used as oncolytic agents in cancer virotherapy approaches. Adenoviruses possess an 
inherent potential to lyse the cells they replicate in, but to avoid side effects in normal 
tissue their replication has to be rigorously controlled. Oncolytic virotherapy relies on the 
delivery of the viral genome to the target tissue, and in the context of disseminated 
disease, systemic delivery is a prerequisite for successful treatment. Therefore, the cancer 
cell transduction and viral replication must be controlled by genetic engineering of the 
viral genome to gain effective and safe tumor eradication. During the last decade, the 
interests of the cancer gene therapy field have focused on identifying the most effective 
tumor targeting approaches and means to tightly control replication of the oncolytic agents 
to avoid replication related toxicity to normal tissue. Furthermore, the balance between 
evading viral neutralizing immunity and enhancing the immune responses against cancer 
cells containing replicating virus within is a major focus of interest. 
2 Cancer 
Cancer is thought to be the result of sporadic and/or inheritable genetic mutations in 
somatic or germline cells (Edler and Kopp-Schneider 2005). Cancer cells are 
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characteristically different from normal cells. They display uncontrolled growth, loss of 
contact inhibition, loss of differentiation and increased invasiveness (Leber and Efferth 
2009). They are also capable of inducing neoangiogenesis, i.e. the formation of small 
capillaries for constant supply of nutrients and oxygen as well as removal of metabolic 
waste. Importantly, cancer cells evade the host immune system and normal apoptotic 
restraints, and are essentially immortalized through chromosome telomere-lengthening 
(Bodnar et al. 1998). All these characteristics play a role in carcinogenesis and the 
differentiation of a normal cell to a malignant cell. 
 In sporadic cancer, expression of active oncogenes leads to uncontrolled cell 
proliferation (Kenemans et al. 2004). Other genetic mutations, mainly in TSGs, are then 
postulated to lead to malignancy. Oncogenes represent genetic alterations in 
proto-oncogenes, i.e. genes normally involved in cellular pathways regulating cell growth 
and differentiation (Edler and Kopp-Schneider 2005). These alterations are called gain-in-
function mutations that ultimately send the cell from resting stage into cell division, and 
are comparable to stepping on the accelerator of a car. Oncogenes mediate their impact 
through either excess amounts of the protein product, due to amplification of the gene or 
overexpression of the protein, or through functional enhancement of the protein (Osborne 
et al. 2004). 
While oncogenes essentially promote cell growth and proliferation, TSGs inhibit them 
(Kenemans et al. 2004). Their normal function is equivalent to stepping on the brakes. 
TSGs are called gatekeeper or caretaker genes, as they are responsible for restraining cell 
division or ensuring that DNA is not damaged (Osborne et al. 2004). Mutations in these 
genes are called loss-of-function mutations, and terminate the cell quiescence or cause 
resistance to apoptosis, thereby allowing cell proliferation. 
A tumor that has not yet reached an invasive and metastasizing phenotype is often 
referred to as carcinoma in situ. Invasiveness refers to the ability to actively invade and, 
thus, destroy adjacent tissues (Leber and Efferth 2009). Metastasis refers to the ability to 
leave the primary tumor, circulate to a distant site, and form a secondary tumor. The 
metastatic cascade consists of five steps:  
1) Invasion and migration: cells detach from the primary tumor and invade 
adjacent tissue with the help of secreted lytic enzymes that degrade the 
extracellular matrix (ECM). 
2) Intravasation: cancer cells secrete proteolytic enzymes and thereby intrude 
blood and lymphatic vessels. 
3) Circulation: cancer cells travel via the blood stream and undergo selection for 
particularly resistant and aggressive phenotypes with the ability to withstand the 
high oxygen concentration and evade cytotoxic lymphocytes present in blood. 
4) Extravasation: cancer cells leave the circulation with the help of proteolytic 
enzymes and invade into tissue. 
5) Colonization, proliferation and angiogenesis: a cancer cell settles at a distant 
site, forms a secondary tumor by proliferation, and ensures vascularization by 
neoangiogenesis. 
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2.1 Cancer stem cells 
Normal stem cell characteristics include the capability of self-renewal, strict control over 
stem cell numbers and the ability to form phenotypically diverse tissues (Morrison et al. 
1997). Similarily to normal stem cells, cancer initiating cells (CIC) have extensive 
proliferative potential and the ability to form new tissues, but they seem to lack control 
over cell numbers (Sagar et al. 2007). Most tumors have a clonal origin, which implies 
that CICs must give rise to phenotypically diverse cell populations with varying 
proliferative potential and different stages of differentiation (Reya et al. 2001), suggesting 
that referring to CICs as cancer stem cells (CSC) is warranted. CSCs undergo a poorly 
regulated process of organogenesis, resulting in the formation of phenotypically diverse 
tissues. As a result, tumors can be viewed as aberrant organs initiated by a CSC.  
 
Figure 1. Hypotheses of cancer stem cell origin. Cancer stem cells may be derived from normal 
stem cells that have acquired mutations and have altered proliferative pathways. They may also 
develop from normal progenitor cells that go through multiple oncogenic mutations and acquire 
the ability to self-renew. 
The origin of CSCs is debatable, but they are postulated to be derived from either the 
self-renewing normal stem cells that have transformed via altered proliferative pathways, 
or from progenitor cells that have acquired the ability for self-renewal through oncogenic 
mutations (Al-Hajj et al. 2004) (figure 1). The cancer stem cell model for cancer adds the 
silencing of the genes controlling stem cell self-renewal and proliferation as one key event 
to tumorigenesis in addition to the role of oncogenes and TSGs.  
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 CSCs can be distinguished from nontumorigenic cells by specific cell surface 
markers. The presence of a transmembrane glycoprotein CD133 has been reported as a 
CSC marker for breast, colon and liver tumors to name a few (Boman and Wicha 2008; 
Vermeulen et al. 2008; Wright et al. 2008). Due to the CSC heterogenicity within a tumor 
and between different patients, a single marker may be a poor distinguishment and the use 
of multiple markers is considered more reliable, though less specific (Saini and 
Shoemaker). Putative breast CSCs presumably reside in the population positive for CD44 
expression and negative or scarce for CD24 expression (Al-Hajj et al. 2003).  This subset 
of CD44+/CD24-/LOW breast cancer cells was enough to form tumors with an inoculation of 
as few as 100 cells in NOD/SCID mice, while tens of thousands of cells of the other 
populations failed.  
The existence of putative CSCs has major implications for cancer treatment. Relapses 
that are often observed after chemotherapy are thought to result from the existence of 
drug-resistant CSCs (Li et al. 2008; Gillette and Nielsen-Preiss 2009). The drug-resistant 
phenotype may be partially explained by the presence of APC transporters that have a 
well-defined role in drug efflux (Gottesman et al. 2002). Furthermore, it has been 
postulated that in a given time most CSCs are not active in the cell cycle, which explains 
why CSCs are able to evade the therapeutic effects of most current treatment methods that 
kill proliferative cells (Sneddon and Werb 2007; Saini and Shoemaker). CSCs might also 
have enhanced DNA repair machinery and a higher tolerance for mutations due to 
disrupted apoptosis machinery (Johannessen et al. 2008).  
2.2 Breast cancer 
Over 1,1 million women are diagnosed annually with breast cancer (Parkin et al. 2005). 
Breast cancer treatment has advanced significantly over the last few decades with 
biological treatment modalities emerging as treatment options to be used alongside more 
conventional methods such as surgery, chemotherapy and radiation therapy (Di Cosimo 
and Baselga 2008; Tanaka et al. 2009). Mammographic screening has led to earlier 
diagnosis of smaller tumors with no lymph node metastasis and the benefit of adjuvant 
(post-operative) chemotherapy in combination with surgery is evident. Albeit 
extraordinary progress in understanding the molecular mechanisms underlying 
carcinogenesis, breast cancer remains the leading cause of cancer related mortality in 
women globally (Parkin et al. 2005). In 2008, more than 800 women died of breast cancer 
in Finland (www.cancerregistry.fi). Despite recent advances, metastatic breast cancer 
remains an incurable disease by current treatment methods. Metastatic breast cancer 
features a median survival of approximately 2 years, with a 5-year survival rate of 19 % 
(Gloeckler Ries 2007). Current therapies are limited by the emergence of therapy-resistant 
cancer cells (Al-Hajj et al. 2003). 
Malignant breast cancer is a complex disease and the progression of normal to 
malignant breast tissue is not completely understood. A multistep carcinogenesis model 
has been proposed to describe the progression of breast cancer most accurately (Beckmann 
et al. 1997). The normal breast epithelium is thought to evolve via hyperplasia and 
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carcinoma in situ, into invasive cancer. Precursor lesions, such as atypical hyperplasias, 
are benign lesions of the breast and carcinoma in situ a malignant transformation without 
stromal invasion across the basement membrane (Kenemans et al. 2004). When such cells 
detach from the basement membrane and invade the stroma, they become invasive and can 
thereafter disseminate via the blood and lymph vessels into lymph nodes or distant organs, 
forming metastases. Breast cancer metastasis is a complex biological process and its risk 
can be predicted by the gene expression profile of the primary breast cancer tumor (de 
Snoo et al. 2009), though clinicopathological data and the extent of the disease still remain 
the most important predictive factors. 
2.2.1 Molecular mechanisms of breast cancer 
Sporadic disease is the predominant form of breast cancer. Oncogene amplification is a 
common mechanism in the development of sporadic breast cancer, and it has been 
estimated that after progression to a malignant, metastasizing phenotype, a single breast 
cancer cell may have a few hundred genes with altered expression patterns (Kenemans et 
al. 2004). Yet, only a few oncogenes seem to be essential for breast cancer development. 
These include the Human epidermal growth factor receptor tyrosine kinase gene 
(HER2/neu), c-Myc, and cyclin D1 (CCNDI) (Beckmann et al. 1997). These genes share a 
common denominator, i.e. having central roles in fundamental cellular events such as 
growth, differentiation, proliferation, and apoptosis. HER2 is a transmembrane receptor 
that acts as an activator in intracellular signaling pathways (Slamon et al. 1989). It is 
amplified or the HER2 protein is overexpressed in approximately 25 % of breast cancers 
(Pauletti et al. 2000; Suter and Marcum 2007). Women with HER2 overexpressing breast 
cancers have an aggressive disease with a significantly shorter disease-free and overall 
survival. HER2 amplification is considered an independent adverse prognostic factor 
(Slamon et al. 1987). C-Myc is a ubiquitously expressed transcription factor belonging to 
the family of myc proto-oncogenes (Verykokakis et al. 2007; Hynes and Stoelzle 2009). 
Its expression is influenced by numerous signaling pathways that are frequently 
deregulated in cancer, and thereby its normal functions are likely to be altered by some 
mechanism in most cancers. In breast cancer, amplification is the most common alteration 
of c-Myc. The cyklin D1 protein plays an important role in the G1/S check point of the cell 
cycle, and its overexpression correlates with progression and poor prognosis (Takano et al. 
1999).  
A much more infrequent form of breast cancer, hereditary breast cancer, is the result of 
inheritable mutations in susceptibility genes, or TSGs, and accounts for 5–10% of all 
breast cancers (Osborne et al. 2004; Carroll et al. 2008). Both alleles of TSGs must be lost 
for the malignant phenotype to occur. BRCA-1 or 2 are mutated in only 0.12% of the 
general population, but are associated with a lifetime risk of approximately 50-90%  in 
defect carriers (Rahman and Stratton 1998). In addition to inherited abnormalities in 
susceptibility genes, TSGs play a role in sporadic cancer and are considered as genes 
whose loss of function results in the promotion of malignancy. Perhaps the most studied 
TSG is p53, which is estimated to be mutated in approximately 20-30% of breast cancers 
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(Hollstein et al. 1991). p53 regulates cell division, and it is rapidly increased when DNA 
damage occurs. Its expression leads to cell cycle arrest and enables DNA repair machinery 
functions, or, in case of extensive DNA damage, p53 can trigger apoptosis by interacting 
with other cellular proteins (Lane et al. 1994; Levine 1997). 
2.2.2 Current treatment options of breast cancer 
Surgery and radiation therapy may be adequate treatment for patients with local breast 
cancer. In case of locally advanced disease, however, surgery and radiation merely offer 
local control and additional therapy is needed due to possible distant metastasis (Liu et al. 
2010). Currently, three systemic treatment modalitites are available for treating breast 
cancer: chemotherapy (CT), endocrine therapy (ET), and biologic (or targeted) therapy 
(BT). A combination of these is referred to as neoadjuvant (pre-operative) or adjuvant 
(post-operative) therapy, which is the standard of care for patients with locally advanced 
breast cancer, as well as for patients with inoperable inflammatory breast cancer. 
Conventional cancer therapies are associated with serious side effects that necessitate the 
development of novel therapies with less adverse effects. 
Anthracyclins, taxanes and alkylating agents such as cyclophosphamide represent 
some of the chemotherapeutics commonly used as adjuvant therapy for early breast cancer 
(Liu et al. 2010). Chemotherapeutics are often associated with adverse side effects, some 
of which are even life threatning, such as neutropenia (Tanaka et al. 2009). Available 
cytotoxic agents are not selective in their activity, and therefore they nonspecifically 
damage normal replicating cells in the bone marrow, gastrointestinal epithelia, and hair 
follicles. For example, acute toxicities associated with doxorubicin, a common 
chemotherapeutic agent used in the treatment of breast cancer, include myelosuppression, 
nausea, vomiting, mucositis and alopecia.  
Endocrine therapy is used when a tumor has a positive estrogen receptor (ER) and/or 
progesterone receptor (PR) status, i.e. it is hormone responsive. The first systemic 
endocrine therapy agent approved for the treatment of advanced disease was tamoxifen, an 
antagonist of the estrogen receptor (Jordan and Koerner 1975). Tamoxifen inhibits the 
growth promoting effects of estrogen. It is also associated, however, with side effects 
including a 2.4 fold increased risk for endometrial cancer (Fisher et al. 2005) and a nearly 
2 fold increase in risk for thromboembolic disease (Cuzick et al. 2003). A more novel 
approach for endocrine therapy is the use of aromatase inhibitors which inhibit the 
synthesis of estrogens in the adrenal glands and adipose tissue, thus lowering the level of 
estrogen and thereby inhibiting tumor growth (Liu et al. 2010). 
A HER2 positive breast cancer can be treated with trastuzumab, a recombinant 
humanized monoclonal antibody against the HER2 receptor (Hudis 2007). Trastuzumab 
represents targeted biologic therapy, and it was first tested in clinical trials in the 1990´s 
and was found to inhibit tumor growth when used as a single agent and to have synergistic 
effects when used in combination with chemotherapeutics (Greenberg et al. 1996). 
Trastuzumab is associated, however, with serious heart problems such as ventricular 
dysfunction and congestive heart failure (Tanaka et al. 2009). 
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A a possibility exists of a curative, multidisciplinary therapeutic approach for a small 
fraction of patients with metastatic breast cancer, when “cure” is perceived as rendering 
the disease harmless for prolonged periods rather than destroying every cancer cell(Pagani 
et al. 2010). When treated with a combination of therapies, and even surgery of the 
metastatic lesions, 1-3% of patients with solitary or a few metastatic lesions may remain 
free of overt disease for prolonged periods, even beyond 20 years (Tomiak et al. 1996; 
O'Shaughnessy 2005). Unfortunately, despite an initial response to endocrine, cytotoxic, 
targeted, or combination therapy, most patients with metastatic disease develop 
progressive disease within 12-24 months with less than five percent of patients surviving 5 
years. Often metastatic disease is treated with palliative care, but perhaps a more balanced 
treatment philosophy could be a quality of life oriented approach with more personalized 
treatment that has reasonable risk to benefit ratio (Pagani et al. 2010). Nevertheless, novel 
and potent methods for the treatment of disseminated disease are called for.  
2.3 Ovarian cancer 
Ovarian cancer is the leading cause of mortality due to gynecological cancers in developed 
countries, causing annually an estimated 125 000 deaths globally (Parkin et al. 2005). 
Ovarian tumors are classified as serous, mucinous, endometroid, clear cell, 
undifferentiated and unclassified (Heintz et al. 2001). Ovarian cancer presents at an early 
stage in approximately 25% of patients with a good prognosis (Pomel et al. 2007). Due to 
mild symptoms in the early stages and lack of screening methods, however, ovarian cancer 
is often diagnosed at an advanced stage (FIGO stages III and IV), resulting in poor 
prognosis. Ovarian carcinoma commonly metastasizes to the peritoneum with frequent 
diaphragmatic, liver-surface, pleural, and pulmonary involvements. A 5-year survival rate 
of patients with metastatic disease is only approximately 20-30%(Gloeckler Ries 2007).  
2.3.2 Current treatment options for ovarian cancer 
Often ovarian carcinoma is diagnosed at an advanced stage of the disease, which makes 
curative treatment virtually impossible. Ovarian carcinoma is commonly treated with 
cytoreductive surgery and adjuvant platinum-based chemotherapy (Pomel et al. 2007). 
Novel therapies for ovarian carcinoma are under development, but no biologically targeted 
drugs have been approved yet. Ovarian carcinoma has been shown to upregulate HER2, 
and therefore trastuzumab therapy was studied as a novel targeted treatment method, 
unfortunately with disappointing results (Bookman et al. 2003). Recently, interest in 
trastuzumab therapy has risen again, as it apparently sensitizes ovarian cancer cells to 
EGFR-targeted drugs (Wilken et al. 2010). Nevertheless, novel therapeutics are 
desperately needed for the treatment of ovarian carcinomas. Oncolytic adenoviruses may 
prove to be efficient in this context, as ovarian carcinoma most often disseminates within 
the peritoneal cavity, allowing direct locoregional delivery that would circumvent possible 
side-effects related to systemic delivery. 
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3 Adenoviral  Cancer Gene Therapy 
Originally, the use of viruses in the treatment of cancer originated from the observation 
that cancer patients who contracted an infectious disease went into brief periods of clinical 
remissions (Kelly and Russell 2007). Adenoviruses were first isolated from adenoids 
during adenoidectomy in 1953 (Rowe et al. 1953). The 1950s and 1960s were periods of 
intense virotherapy research as the development of cell and tissue culture systems allowed 
ex vivo virus propagation (Kelly and Russell 2007). Adenovirus was first used in a clinical 
trial for cervical carcinoma as early as 1956. In retrospect it is not surprising, that no 
treatment associated benefit was seen, as the viral characteristics were not really known 
and therefore dosage, delivery route, replication potential, and safety of the virus were 
suboptimal. Even though adenoviral inoculations did not cause serious side effects, 
virotherapy was abandoned as a cancer treatment due to the fact that only a few clinical 
responses were reported, the effects of viruses were unpredictable, and development of 
effective chemotherapeutics more or less supplanted it (Wildner 2001). Methods for large-
scale production of high-titer purified adenovirus and quantitation of its biological activity 
were also insufficient at the time.  
Even before recombinant DNA technology became available, it was suggested that 
altering the viral genome would improve the targeting of oncolytic viruses (Southam 
1960). In the 1990s this idea became reality, as recombinant DNA techniques allowed 
genetic engineering of viruses. Ever since adenoviruses have been extensively studied and 
developed for gene delivery purposes, as well as for oncolytic virotherapy. Adenoviruses 
have various advantageous characteristics for genetic manipulation and gene therapy. The 
genome of most widely used strains, serotype 5 (Ad5) and serotype 2 (Ad2), are well 
characterized and can be manipulated fairly easily, produced and purified to high titers, 
their genomes rarely integrate into the host genome, which is suitable for virotherapy that 
does not require stable gene expression, and they have a good safety profile in humans 
(Danthinne and Imperiale 2000).  
The first adenoviral cancer gene therapy approaches with genetically engineered 
viruses utilized non-replicating agents that aimed at transferring a gene for correction of 
the disease phenotype or expression of therapeutic molecules inside or near the target cell 
(Brody and Crystal 1994; Clayman et al. 1995). Virotherapy is a novel approach that relies 
on the natural replication potential of Ads and the ability of the virus to kill the cancer 
cells (i.e. oncolysis) that are permissive for viral replication. Moreover, progeny virions 
infect neighboring cells and thereby display potential to amplify the therapeutic effect of 
the initial viral dose (figure 2). Relentless research efforts have provided various means 
for control over replication and target tissue transduction to improve safety and efficacy of 
oncolytic vectors. 
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Figure 2. Oncolytic adenoviruses infect both normal and cancer cells, but are only 
able to replicate in cancer cells. Progeny virions are relased from dying cells and the 
therapeutic effect of the initial viral dose is amplified. 
3.1 Adenovirus 
Adenoviruses are common opportunistic pathogens rarely associated with severe clinical 
symptoms in healthy adults (Lenaerts et al. 2008). Adenoviruses are known to infect 
humans via the respiratory, the fecal-oral, or the ocular conjunctival routes (Kojaoghlanian 
et al. 2003). Adenoviral infections are endemic and frequent in humans and are associated 
with a broad range of symptoms, such as upper and lower respiratory tract disease, 
conjunctivitis and gastroenteritis (Lenaerts et al. 2008). Diseases are usually mild in 
immunocompetent humans, but can lead to disseminated and potentially life-threatening 
disease in patients with compromised immunity, such as AIDS patients and transplant 
recipients (Kojaoghlanian et al. 2003). 
Adenoviruses belong to the family of Adenoviridae, which is subdivided into four 
genera (Siadenovirus, Aviadenovirus, Atadenovirus, and Mastadenovirus) (Davison et al. 
2003). All human adenoviruses belong to the genera Mastadenovirus. There are 51 
different serotypes of adenoviruses that were originally classified depending on the ability 
of different animal sera to neutralize them (Russell 2009). They can be further divided into 
six different subgroups of A-F based on their ability to agglutinate erythrocytes of 
different species and their oncogenicity on rodents. Ad5 from subgroup C is the most 
widely studied adenovirus, and is the serotype mainly discussed in this thesis. 
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3.1.1 Adenovirus structure and life cycle 
Adenoviruses are non-enveloped viruses 70-90 nm in diameter with an icosahedral capsid. 
Their genome is linear, double stranded DNA varying between 25-45 kilobases in size 
with inverted terminal repeats (ITRs) at both termini and a terminal protein attached to the 
5´ends (Rekosh et al. 1977; Russell 2000). 
The icosahedral capsid is formed by three major proteins, of which the hexon trimers 
are most abundant (figure 3) (Nemerow et al. 2009). Each of the twelve vertices of the 
capsid also contains a pentameric protein, a penton base that is covalently attached to the 
fiber. The fiber is a trimeric protein that protrudes from the penton base and is a knobbed 
rod-like structure (Nicklin et al. 2005). Other viral proteins such as IIIa, VIII, and IX are 
also associated with the viral capsid (Vellinga et al. 2005). 
All human adenoviruses have similarities in their fiber architecture. Each has an 
N-terminal tail, a shaft with repeating sequences, and a C-terminal knob domain with a 
globular structure (Nicklin et al. 2005). The knob domain is principally responsible for 
binding the target cellular receptor and its globular structure presents a large surface for 
lateral and apical binding. The fiber proteins of adenoviruses from different subgroups 
most distinctively differ in length and ability to bend. 
 
 
 
Figure 3. Adenovirus structure. The adenovirus capsid is icosahedral, comprising of 
20 facets and 12 vertices with a penton structure. Each facet is comprised of 20 
hexons. The penton capsomere is comprised of the homopentameric penton base and 
the homotrimeric fiber. The fiber has three distinct regions, the tail, shaft, and knob. 
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Adenovirus trafficking can be characterized by five stages: binding, entry, escape, 
translocation, and nuclear transport (Leopold and Crystal 2007). Initially the fiber knob 
binds a primary receptor with high affinity and once the virus is tethered on the cell 
surface, low affinity binding to secondary receptors leads to internalization (Wickham et 
al. 1993). Adenoviruses enter cells via dynamin dependent chlatrin-mediated endocytosis 
(Wang et al. 1998). Escape from the endosome into the cytosol occurs within minutes and 
is dependent on the acidification of the endosome (Leopold and Crystal 2007). 
Acidification triggers changes in the adenoviral capsid resulting in the lysis of the 
endosome membrane. Once in the cytosol, adenoviral capsids translocate towards the 
nucleus along the microtubules by interacting with cellular molecular motors, such as 
cytoplasmic dynein (Leopold et al. 2000). Thereafter, the adenoviral genome is 
transported inside the nucleus via nuclear pores (Saphire et al. 2000; Trotman et al. 2001).  
3.1.2 Adenoviral transcription and replication 
Adenoviruses are dependent on the cellular machinery to replicate the viral genome 
(Moran 1993). They can infect quiescent cells and induce them into a cell cycle S-phase-
like state enabling viral DNA replication. The adenoviral genome can be divided into 
immediate early (E1A), early (E1B, E2, E3, E4), intermediate (IX, Iva), and late (L1-L5) 
genes (figure 4) (Russell 2000).  
Adenoviral transcription can be described as a two-phase-event, early and late, 
characterized by the expression of different viral genes and separated by the onset of viral 
DNA replication (Russell 2009). The first transcription unit to be expressed is the E1A. 
The E1A proteins stimulate the transcription of other early genes and modulate the 
expression of cellular genes involved in the transition into S-phase, making the cell more 
susceptible to viral DNA replication (Berk 1986a; Berk 1986b; Volpers and Kochanek 
2004). The E1B proteins suppress cell death elicited in response to unregulated cell 
proliferation signals, including those mediated by E1A (Moran 1993). The E2 gene 
products provide the replication machinery for viral gene products.  
E3 gene products are not essential for virus replication in vitro, but are dedicated to the 
control of various host immune responses (Horwitz 2004). E3-gp19K inhibits the transport 
of the class 1 major histocompatibility complex (MHC) from the endoplasmic reticulum 
(ER) to the plasma membrane, thereby preventing the presentation of peptides to T 
lymphocytes by MHC (Rawle et al. 1989; Schowalter et al. 1997). Other E3 proteins 
inhibit apoptosis elicited by various cellular proteins such as the tumor necrosis factor α 
(TNFα) (Wold 1993). As an exception, E3 derived adenoviral death protein (ADP) 
functions late in the viral cycle to promote cell death, presumably to aid in the release of 
of the virus after all the replicative functions have been completed (Tollefson et al. 1996).  
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 Figure 4. Organization of the adenovirus genome.  Early transcripts E1A to E4, 
intermediate transcripts IX and Iva, and late transcripts L1 to L5. MLP stands 
for major late promoter. Modified from Russel et al. 2000. 
E4 gene products have been implicated in many events that occur as the late program 
begins. E4 proteins augment viral DNA synthesis and messenger RNA (mRNA) transport, 
late viral gene expression, shutoff of host protein synthesis, and production of progeny 
virions (Halbert et al. 1985; Bridge and Ketner 1989; Bridge and Ketner 1990; Goodrum 
and Ornelles 1999). The late gene transcription leads to the production of viral structural 
components and the encapsidation and maturation of the viral particles in the nucleus. 
3.1.3 Adenoviral transduction 
The primary receptor for subgroup C adenoviruses is the coxsackie adenovirus receptor 
(CAR) (Bergelson et al. 1997). The expression levels of CAR correlate with the 
susceptibility of a particular cell type to adenoviral infection (Asaoka et al. 2000). 
Furthermore, the induction of CAR expression leads to improved transduction on cells that 
are naturally refractory to adenoviral infection (Nalbantoglu et al. 2001). Also, CAR 
localization on the cell surface affects the infection. CAR has been shown to localize to 
the basolateral surface of polarized epithelial cells, thereby hindering adenoviral infection 
through the apical surface, and to the tight junctions, thereby acting as a natural barrier 
against infection through the basolateral surface as well (Walters et al. 1999; Cohen et al. 
2001). CAR expression is variable and often low on cancer cells and CAR levels on 
cancer tissues inversely correlate with tumor aggressiveness (Kim et al. 2002).  
Cellular integrins are cell surface adhesion molecules that many adenoviruses utilize as 
secondary receptors. The Arg-Gly-Asp (RGD) or Leu-Asp-Val (LDV) motif in the penton 
base interacts with αvβ3 and αvβ5  integrins as well as αvβ1, α5β1, and  α3β1 to activate 
viral internalization (Wickham et al. 1993) (Davison et al. 2001; Li et al. 2001; Salone et 
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al. 2003). The importance of the viral interaction with integrins is highlighted by the fact 
that multiple serotypes from different subgroups contain a conserved RGD motif (Mathias 
et al. 1994). Nevertheless, adenoviral infection can occur even in the absence of an 
integrin-penton base interaction, suggesting that the fiber-CAR interaction is sufficient to 
allow virus entry, albeit at a significantly reduced internalization rate (Bai et al. 1993). 
The integrins interact with a variety of signaling molecules and the Ad-integrin interaction 
thereby promotes activation of phosphatidylinositol-3 kinase (PI3K) and Rho family 
GTPases, which are involved in actin cytoskeleton reorganization (Nemerow and Stewart 
1999). Polymerized actin filaments assist dynamin-mediated endosome formation 
(Doherty and McMahon 2009). 
Besides CAR and integrins, various other receptors for adenoviruses have been 
proposed. CD46, a transmembrane glycoprotein normally acting to prevent complement 
activation of autologous tissue, has been identified as a cellular receptor for the majority 
of subgroup B adenoviruses (Segerman et al. 2003; Fleischli et al. 2007), although CD46 
usage by serotype 3 remains controversial (Marttila et al. 2005; Tuve et al. 2006; Fleischli 
et al. 2007). CD80 and CD86 expressed on the surface of antigen presenting cells (APCs), 
such as dendritic cells and B lymphocytes, have been shown to mediate subgroup B 
adenoviral infection (Short et al. 2004). Furthermore, the existence of an additional 
receptor for subgroup B adenoviruses distinct from CD46 and CD80/86 has been 
suggested and is being referred to as species B adenoviral receptor (sBAR) or receptor X 
(Sharma et al. 2009).  
Proteoglycans, the major histocompatibility complex class 1 (MHC-1), and sialic acid 
have also been implicated as adenovirus receptors. Proteoglycans form the major 
component of the extracellular matrix (ECM) and are involved in various cellular 
functions such as cellular attachment and proliferation (Bishop et al. 2007). Pathogens 
have evolved to exploit prevalent proteoglycans as receptors and heparin sulphate 
proteoglycans (HSPG) are involved in the infection of Ad5 and Ad2 (Dechecchi et al. 
2001). A consensus sequence Lys-Lys-Thr-Lys (KKTK) in the fiber shaft was suggested 
as the HSPG binding motif (Dechecchi et al. 2001). Hepatocytes express high amounts of 
HSPG and the KKTK motif contributes to the hepatotropism of adenoviruses (Smith et al. 
2003b). Vitamin K dependent circulating coagulation factors VII, IX and X (FVII, FIX 
and FX) as well as complement protein C4BP seem to bind adenovirus and direct these 
complexes to HSPGs, as well as LDL receptor related protein (LRP) expressed on liver 
cells (Shayakhmetov et al. 2005; Parker et al. 2006). The α2 domain of the MHC-1 heavy 
chain binds to Ad5 and Ad2 fiber (Hong et al. 1997) and it may play a role in Ad 
internalization in the absence of CAR or improve the accessibility of CAR to the fiber 
(Davison et al. 1999). Finally, an epidemic keratoconjunctivitis causing subgroup D 
adenoviruses use negatively charged sialic acid as a cellular receptor (Arnberg et al. 2000; 
Sharma et al. 2009). 
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3.1.4 Adenovirus induced immunity 
Adenoviruses have not evolved efficient immune tolerance mechanisms, so the  immune 
system strongly recognizes them as immunogens (Tuve et al. 2009). Although 
adenoviruses have been proven relatively safe in clinical trials, both innate and adaptive 
immune responses need to be considered when treating humans. Research and clinical 
experience with first generation E1/E3-deleted vectors revealed that significant host 
immune responses limit the utility of adenoviruses in gene therapy (Muruve 2004). 
Adenoviruses may elicit acute inflammation resulting in significant reduction in gene 
transfer efficacy and vector persistance (Worgall et al. 1997), and in the worst case 
scenario, damage to healthy tissue and even death (Raper et al. 2003). Adenovirus-induced 
acute toxicity is dose-dependent and independent of viral gene expression, which indicates 
that viral capsid proteins elicit the immune reaction (Muruve et al. 1999).  
Adaptive immune responses to adenoviruses may be a major hurdle to the efficacy of 
adenoviral gene therapy especially if long-term transgene expression is desired, since the 
cytotoxic T-cell response against infected cells results in transient transgene expression 
(Leen et al. 2008). On the other hand, adenovirus-specific T-cell responses can be 
exploited in cancer immunotherapy approaches (Tuve et al. 2009). The adenovirus-
specific immunity may be exploited to gain additive or synergistic anti-tumor effects 
(Prestwich et al. 2008).  
3.1.4.1 Innate immunity 
The innate immune system represents the first line of defence against invading pathogens 
and is comprised of cells, immune mediator proteins including chemokines, cytokines and 
complement proteins, and pattern recognition receptors (PRR), that recognize pathogen 
associated molecular patterns (PAMPS) (Zaiss et al. 2009). The most studied receptors are 
the Toll-like receptors (TLRs) that are also linked to the type I interferon (IFN) responses 
(Vaidya and Cheng 2003). IFNs are cytokines that induce complex antiviral resistance 
mechanisms in cells. Other adenovirus induced cytokines include the TNF-α and 
interleukins-1,-6, and -12 (Muruve 2004). Also various chemokines are secreted upon 
adenoviral infection, including macrophage inflammatory proteins (MIP)-2, -1α, and -1β, 
as well as IFN-γ-inducible protein 10 (IP-10). The induction of multiple cytokines and 
chemokines is relatively rapid after adenoviral infection, occurring within a few hours or 
less (Otake et al. 1998; Muruve et al. 1999). The induction of these immune mediators 
correlates with the inflammatory response within adenovirus transduced organs (Otake et 
al. 1998) and has a major role in recruiting and activating innate effector cells to sites of 
infection (Guidotti and Chisari 2001) and, for example, in subsequent liver damage 
(Muruve et al. 1999). The acute cytokine response is mediated by dendritic cells (DCs) 
and macrophages (Zhang et al. 2001). 
Kupffer cells (KCs) are resident liver macrophages that act as effector cells and 
effectively take up systemically administered adenoviruses (Zhang et al. 2001). The 
blockade of KCs reduces adenovirus-induced cytokine-mediated inflammation and 
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improves gene transduction (discussed in more detail later) (Kuzmin et al. 1997; 
Schiedner et al. 2003; Koski et al. 2009). Adenovirus clearance from blood by KCs is 
saturatable, probably due to exceeding the phagocytic capacity of these cells (Tao et al. 
2001). 
Along with KCs, adenovirus transduced DCs play a critical role in the early innate 
immune responses by interacting with other innate immune cells including natural killer 
cells (NK), mast cells, and neutrophils (Prestwich et al. 2008). Furthermore, DCs are the 
principal cross-presenting (i.e. presenting exogenous antigen in MHC) antigen presenting 
cells (APC) in vivo and act as an important link between the innate and adaptive immunity 
(Schulz et al. 2005). Upon natural stimuli, such as pathogen encounter, DCs mature and 
can migrate to T-cell rich areas of secondary lymphoid organs where they cross-present 
antigens in an appropriate costimulatory environment to the adaptive arm of the immune 
system (Mercier et al. 2004).  
3.1.4.2 Adaptive immunity 
T-cell response is provoked upon migration of mature DCs to secondary lymphoid organs. 
DCs stimulate T-cells via costimulatory molecules CD40, CD86, and CD28/80 and 
present viral antigens, either processed capsid proteins from random uptake or virus 
expressed proteins from viral DNA that has reached the nucleus, via MHC I molecules to 
generate CD8+ cytotoxic T-cells (CTL) or via MHC II molecules to generate CD4+ 
T-helper (TH) cells (Perreau and Kremer 2006). Depending on the cytokines produced by 
DCs, TH are further differentiated into TH1 (cellular response) or TH2 (humoral response). 
Furthermore, the cytotoxic T-cell generation requires DC secreted costimulatory cytokines 
and TH functions in addition to antigen presentation by MHC I. Finally, the CD4+ TH-cells 
and CD8+ CTL kill virus infected cell. 
TH2 cells play a central role in the generation of memory B cells, i.e. plasma cells 
(McHeyzer-Williams and McHeyzer-Williams 2005). Naïve B cells internalize viral 
particles through B-cell receptors and process them. Thereafter, viral epitopes are 
presented to TH2 cells via MHC II, which finally leads to extensive clonal expansion of 
antigen-specific B-cells into short-lived antibody-secreting plasma cells, rapidly 
expanding centroblast or quiescent noncycling centrocytes. Through diverse steps, some 
of the expanding B-cells develop into memory B-cells. Upon reencountering the specific 
antigen epitope clonal expansion of the specific memory B-cell population occurs, 
resulting in a strong and rapid production of specific antibodies. 
The majority of the human population has been exposed to Ads and thereby have 
developed an adenovirus-specific immune response (Bangari and Mittal 2006). The pre-
existing vector immunity is mediated by serotype specific B-cell produced neutralizing 
antibodies (NAbs) that are directed against the capsid components. Of humans, 40-97% 
have NAbs against Ad5, the most widely used serotype in gene therapy. Nabs bind to 
capsid proteins and block adenoviral internalization to target cells, and elicit induced 
uptake to Fc-receptor bearing immune cells such as KCs and DCs, resulting in rapid 
vector clearance and inflammatory responses (Mercier et al. 2004; Perreau and Kremer 
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2006). Although pre-existing immunity does not seem to adversely affect the antitumor 
efficacy of locally delivered adenovirus (Dhar et al. 2009), a high NAb titer may 
compromise systemic delivery (Chen et al. 2000). Furthermore, NAbs developed in naïve 
individuals within 1 week after a virus encounter have been suggested to aggravate re-
administration attempts. Extensive pre-existing Ad5 immunity is likely to limit clinical 
utility of adenovirus vectors, unless methods to circumvent neutralizing antibodies can be 
developed. The successive use of viruses with different capsid modifications has been 
proposed as a means to circumvent the neutralizing activity of capsid protein specific 
NAbs to some extent (Sarkioja et al. 2008). Furthermore, serotype switching and the use 
of non-human adenoviruses may be useful (Perreau and Kremer 2006). 
Innate and adaptive immune responses may be exploited in the context of oncolytic 
virotherapy. Tumors are able to disrupt anti-tumor immune responses by creating an 
immunosuppressive tumor microenvironment. By secreting soluble immunosuppressive 
mediators, such as IL-10, and by inducing regulatory T-cells, that are able to abrogate 
effective antitumor T-cell responses (Mittendorf and Sharma 2010). In addition to their 
ability to disrupt antitumor immune responses, tumors commonly lack “danger signals” 
that the immune system responds to. For cross-presentation, virally infected cells are 
superior at TLR-3 augmented delivery of nonviral antigen (Schulz et al. 2005). Virally 
induced cell death would be expected to enhance the availability of tumor-associated 
antigens for uptake by DCs (Moehler et al. 2005). Furthermore, viral infection may alter 
the balance of cytokine production from the tumor, and subsequently affect the nature of 
the immune reaction to the tumor, that is, by counteracting the immunosuppressive nature 
of the tumor microenvironment (Prestwich et al. 2008). Moreover, viruses can be 
engineered to express highly immunogenic proteins such as granulocyte-macrophage 
colony-stimulating factor (GM-CSF). When immunogenic proteins are expressed within 
tumor cells, they are potent stimulators of specific and long-lasting antitumor immunity 
(Pan et al. 2009). 
3.2 Transductional targeting of adenoviral vectors 
Loss of CAR expression correlates with tumor progression, which implies low expression 
levels of CAR in advanced disease (Okegawa et al. 2004). Cells expressing low levels of 
CAR are refractory to Ad5 infection, at least in vitro. CAR dependency results in a 
scenario in which the target tissue of adenoviral gene therapy is poorly transduced, i.e. 
viruses enter target cells inefficiently, while non-target tissue with high CAR expression is 
efficiently transduced (Kim et al. 2002).  
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Figure 5. Wt capsid Ad5 and viruses with a single modification in the capsid: 
RGD-modification in the HI-loop of the knob, pK7 modification in the 
C-terminus of the knob, and a serotype 5/3 chimeric fiber with a serotype 3 
knob. 
Adenovirus vector biodistribution in vivo is not solely dependent on receptor 
distribution (Glasgow et al. 2006). High CAR expression does not correlate with tissue 
transduction after systemic application, since the virus is almost exclusively taken up by 
the liver and other high CAR and/or integrin expressing tissues are not transduced 
(Fechner et al. 1999). Various blood coagulation factors play a role in adenovirus tropism 
by bridging adenovirus to cell surface receptors, especially on hepatocytes and liver KCs 
(Shayakhmetov et al. 2005; Parker et al. 2006; Schagen et al. 2008). Also, anatomical 
barriers play a significant role in vector targeting after systemic injection (Fechner et al. 
1999). Intratumoral spread of adenoviruses is very limited due to barriers formed by 
connective tissue or fibroblasts (Li et al. 2004). Large tumors are also often associated 
with hypoxic and necrotic areas that do not support adenoviral spread. 
Taken together, these obstacles make transductional targeting of adenoviral vectors a 
prerequisite for their systemic use. In the context of systemic cancer treatment it seems 
necessary to not only redirect adenoviral tropism to tumors by CAR binding ablation and 
introducing a new attachment molecule, but also to ablate the binding of several blood 
factors directing adenoviruses to the liver. Otherwise efficient transduction of target tissue 
might be accomplished, regardless of the tropism expansion, as the vector will be taken up 
by the liver. 
3.2.1 Genetic modification 
Genetic modification of the capsid is a conceptually elegant approach to redirect 
adenoviral tropism. In short, the goal of genetic targeting is to create a single-component 
vector that can transduce cells via non-native receptors (Noureddini and Curiel 2005). 
Strict constraints are, however, imposed on such efforts by the structural integrity and the 
biological functionality of the virus.  
Fiber is the primarily exploited capsid locale for genetic engineering (figure 5). Four 
basic strategies for genetic tropism modification of the fiber exist: fiber pseudotyping, 
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CAR ablation by short deletions, ligand incorporation into the knob, and “de-knobbing” of 
the fiber coupled with ligand addition (Glasgow et al. 2006). Other capsid locales hexon, 
penton base, and pIX have been modified to lesser extent. 
3.2.1.1 Fiber pseudotyping 
A high degree of structural similarity exists in the fiber protein amino(N)-terminal tail 
region between different serotypes (Rux and Burnett 2004; Zubieta et al. 2005). This 
structural similarity enables the creation of chimeric vectors, where the whole fiber or the 
knob region is switched to that of another serotype. This fiber pseudotyping, or fiber 
chimerism, results in CAR binding ablation and alternate receptor recognition, but is 
limited to the tropic behavior of the characterized serotype adenoviruses (Noureddini and 
Curiel 2005). Previously, altered tropism of the Ad5 vector has been achieved by 
switching the whole fiber to that of serotype B Ads 7, 35, or 16, resulting in the 
transduction of various CAR-deficient tissues and cells such as dendritic cells (DCs), 
hematopoietic stem cells (HSC), and synovial tissues (Gall et al. 1996; Shayakhmetov et 
al. 2000; Goossens et al. 2001; Rea et al. 2001). The use of the serotype 19p fiber in the 
Ad5 vector resulted in efficient transduction of renal cell cancer tumors in mice and 
significantly reduced liver tropism, a useful property for systemic treatment (Diaconu et 
al. 2009). Increased transduction of ovarian cancer cells was achieved by replacing the 
Ad5 knob with the knob from Ad3 (Krasnykh et al. 1996; Kanerva et al. 2002). 
3.2.1.2 CAR binding ablation by short deletions 
Sequence and mutagenesis analysis on the fiber have implicated the AB loop, DE loop, 
DG loop, Bβ sheet, and β strand F as structures on the knob that have relevance in binding 
CAR. Yun et al. ablated CAR binding by deleting the Bβ sheet of the knob and reported 
reduced adenoviral liver tropism and toxicity (Yun et al. 2005). The mutation of the AB 
and DG loop resulted in the loss of CAR-mediated binding in vitro (Leissner et al. 2001).  
3.2.1.3 Ligand incorporation to fiber 
 
CAR independent gene delivery can be achieved by incorporating peptide ligands into the 
knob. This approach does not abrogate the native tropism, as the CAR binding ability is 
retained, but rather expands the vectors tropism. Incorporation of ligands imposes 
structural constraints on the folding and trimerization of knob, however, and therefore 
only a limited number of genetic modifications allow production of functional fiber 
(Borovjagin et al. 2005). Ligands can be incorporated into two distinct locales of the knob: 
the HI loop or the carboxy (C)-terminus. An RGD(arg-gly-asp)-ligand, targeting 
adenoviruses into integrins, or a polylysine (pK) motif, targeting them into HSPGs, have 
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been incorporated into the C-terminus (Wickham et al. 1993; Borovjagin et al. 2005) and 
HI-loop (Krasnykh et al. 1998), or both (Borovjagin et al. 2005). Also, an approach 
termed mosaicism has been utilized, where two distinct ligands were incorporated into the 
serotype 5 fiber (Wu et al. 2002). Complex mosaicism takes this approach even further 
with two ligands incorporated into a chimeric fiber (Borovjagin et al. 2005).  
3.2.1.4 De-knobbing 
Several research groups have developed chimeric attachment molecules, in which the fiber 
knob or knob and shaft have been replaced with an exogenous trimerization domain such 
as the α–helix domain from Moloney murine leukemia virus (MoMuLV) envelope 
glycoprotein (van Beusechem et al. 2000), bacteriophage T4 fibritin protein (Krasnykh et 
al. 2001), the neck region peptide of human lung surfactant protein D (Magnusson et al. 
2001), or the T oligomerization domain of the reovirus attachment protein σ1 (Schagen et 
al. 2008) coupled with various ligands. With this “de-knobbing” approach, binding to 
CAR, integrins, HSPGs, as well as to molecules such as various coagulation factors 
linking adenoviruses to alternative cell surface receptors, is abrogated (Shayakhmetov et 
al. 2005; Parker et al. 2006; Schagen et al. 2008). In theory, this approach completely 
abrogates the native tropism and introduces unique binding motifs that have the potential 
to improve in vivo applicability of adenoviruses (Schagen et al. 2008). Recently, however, 
coagulation factor X (FX) binding to hexon has been claimed to be the major determinant 
of liver transduction, and thereby de-knobbing approaches would not affect this (Alba et 
al. 2009). 
3.2.1.5 Liver detargeting by genetic modification  
The majority of intravenously administered adenoviral vectors are taken up by the liver 
KCs and hepatocytes, and transgene expression is predominantly found in hepatocytes 
(Vrancken Peeters et al. 1996; Connelly 1999; Alemany et al. 2000). Hepatocyte 
transduction ablation has been attempted with various capsid modifications. Smith et al. 
created a mutation in the Ad5 HSPG binding fiber shaft KKTK motif that resulted in 
reduced liver tropism in mice, rats, and non-human primates (Smith et al. 2003a; Smith et 
al. 2003b). Various attempts to modify in vivo adenoviral tropism by abolishing CAR 
and/or integrin interactions have not been successful in detargeting the liver (Alemany and 
Curiel 2001; Smith et al. 2002; Martin et al. 2003) . This implies that the presence of CAR 
is not a critical factor in determining the susceptibility of tissues to adenovirus in vivo, and 
that blood factors serving as a bridge between the virus and liver cells may allow efficient 
liver transduction despite CAR binding ablation (Shayakhmetov et al. 2005; Parker et al. 
2006). Hexon is the major determinant of Ad5 liver tropism and recent studies have 
highlighted the role of the high-affinity interaction of FX with hexon in FX-mediated liver 
gene transfer (Kalyuzhniy et al. 2008; Waddington et al. 2008). Recently, it has been 
shown that mutation of critical amino acids from two hypervariable regions in hexon 
 
 
 
 
31
eliminates FX binding and subsequent FX-mediated liver gene transfer in mice (Alba et al. 
2009). If such minimal modifications would indeed eliminate liver transduction in humans 
as well, this approach would be highly beneficial in oncolytic adenoviruses intended for 
human use. 
3.2.2 Adapter based modification 
Adenoviruses can be physically prevented from binding to their native receptor and 
redirected to other receptors by using bispecific adapter molecules, which bind to the knob 
with one domain and to a target receptor with another (Li et al. 2007). Usually the 
detargeting component of such an antibody is either the soluble CAR ectodomain or an 
antibody to the knob, and the retargeting component is a ligand for cell surface receptor or 
a cellular antigen, such as epidermal growth factor receptor (EGFR) (Dmitriev et al. 
2000), CD40 (Pereboev et al. 2002) or carcinoembryonic antigen (CEA) (Li et al. 2007). 
Bispecific antibodies have demonstrated infectivity enhancement both in vitro and in vivo. 
Their use, however, is limited to non replicating vectors as the non-genetic bispecific 
antibody modification would not be included in the progeny virions in the context of 
oncolytic vectors.  
3.2.3. KC depletion with pharmaceutical agents 
KCs represent the first line of defence against pathogens and can efficiently take up 
intravenously delivered adenoviruses (Wolff et al. 1997; Alemany et al. 2000; Tao et al. 
2001). KC uptake of adenoviruses not only reduces the amount of free virus in the blood 
that can reach the target tissue, but also provokes toxic responses due to cytokine 
induction and antigen presentation, which elicit adaptive responses, such as cytotoxic T-
cell responses (Zaiss et al. 2009). 
Clearance of adenoviruses by KCs is mediated through various routes. Scavenger 
receptors play a major role in the uptake of adenoviruses (Xu et al. 2008; Haisma et al. 
2009), and subsequently preinjections with polyinosinic acid (polyI), a scavenger receptor 
ligand, can greatly reduce viral uptake by KCs and increase the circulating half-life (Smith 
et al. 2008). Furthermore, mouse complement and natural antibodies were shown to some 
extent to contribute to adenovirus uptake by KC (Xu et al. 2008). Other substances used to 
reduce adenovirus uptake by KCs include gadolinium chloride (GdCl3), empty liposomes, 
or clodronate liposomes. Gadolinium chloride not only blocks the phagocytic activity of 
KCs, but also transiently eliminates them (Du et al.). Clodronate is clinically used for 
osteolytic bone disease and when encapsulated into liposomes, is efficiently delivered into 
phagocytic cells such as KCs resulting in their damage and apoptosis (Schiedner et al. 
2003). The use of empty multilamellar liposomes to block KCs is also based on KC 
saturation (Snoeys et al. 2006). The use of liposomes represents a non-toxic means for KC 
blockage, since they do not destroy KCs. In addition to the use of various chemical 
substances, prior injection of a saturating amount of adenovirus vector has also been 
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shown to increase the therapeutic window with a subsequent injection of another vector 
(Shashkova et al. 2008). 
3.3 Transcriptional targeting of adenoviral vectors 
Upon infection, adenoviruses need to induce a cell cycle S-phase-like state in order to 
transcribe and replicate the viral genome. E1A is the first viral protein to be expressed in a 
transduced cell and can activate transcription of other early viral genes by interactions 
with cellular check point proteins (Nemajerova et al. 2008). Importantly, E1A expression 
results in the activation of the E2a promoter and the E2 region transcription, leading to the 
expression of adenoviral replication machinery (Berk 1986a). In oncolytic virotherapy, the 
replication of Ads has to be controlled in order to avoid side effects in normal tissues. 
Furthermore, E1A protein is toxic by itself, and therefore it is beneficial to avoid its 
expression in normal cells.  
The transcriptional regulation of E1A can be achieved by introducing specific genetic 
deletions in the E1A gene that makes the virus dependent on the disruption of central 
cellular regulatory pathways, a typical phenomenon in oncogenesis. Moreover, cellular 
genetic regulatory elements, such as promoters, enhancers, and silencers, can be inserted 
into the adenovirus genome to regulate the transcription of viral E1A or other key 
regulatory genes and/or transgenes. This approach aims at obtaining selective and high 
expression of viral genes in tumor cells as a result of the activity of the cellular regulatory 
element employed. 
3.3.1 Genetic deletions for transcriptional control 
Specific deletions on adenoviral key regulatory genes can be utilized to create 
dysfunctional proteins or the lack of their expression that leads to dependence on a 
specific genetic feature present in cancer cells. Partial deletions of E1A and E1B genes 
result in restricted replication in normal cells but allow replication in cancer cells. 
The adenoviral E1B region encodes the protein E1B-55K that binds and inactivates 
p53, thereby inhibiting apoptosis of adenovirus infected cells. The partial deletion of the 
E1B gene targets adenoviral replication to cells with deleted or mutated p53 TSG, which is 
a frequent phenomenom in cancer cells (Bischoff et al. 1996). The first genetically 
modified adenovirus, ONYX-015, featured a deletion in the E1B rendering E1B-55K 
protein truncated and unexpressed. An additional point mutation was introduced to 
generate a stop codon to prevent expression of the truncated E1B55-K protein. Normally, 
p53 can counterbalance the E2F dependent activation of the cell cycle progression genes 
by inducing the expression of p21, an inhibitor of cyclin A and E dependent kinases 
(Levine 1997). The E1B-55K protein forms a complex with E4orf6 and p53, which leads 
to proteolysis of p53 (Barker and Berk 1987). Since the first publication describing it, 
ONYX-015 and its variants have been widely studied and have entered multiple clinical 
trials. Original studies with ONYX-015 showed that it replicated less efficiently than wt 
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Ad in cells expressing p53(Bischoff et al. 1996) Various subsequent reports have shown, 
however, that ONYX-015 does not cause selective death of p53-deficient cells (Goodrum 
and Ornelles 1998; Rothmann et al. 1998; Harada and Berk 1999), but rather displays 
different cell killing efficiency in a cell line dependent manner due to differencies in 
infectivity or permissiveness, rather than p53 status (Steegenga et al. 1999). 
The dependence of adenoviral replication on specific structures on the E1A protein 
can be utilized to restrict adenoviral replication. The adenoviral E1A protein was 
originally described as a retinoblastoma (pRb) binding protein capable of inducing DNA 
replication in quiescent normal cells (Ruley 1983). pRb regulates the cell cycle 
progression by interacting with numerous cellular proteins. The pRb-E2F complex 
contains an E2F/DP heterodimer stably bound to hypophosphorylated pRb, and acts as a 
transcriptional repressor of E2F responsive genes, such as adenoviral E2a. Under normal 
proliferative conditions, pRb is phosphorylated by cyclin/cdk complexes, disrupting its 
ability to bind to its regulatory targets (Dyson 1998). Remarkably, the advancement of the 
cell cycle to S-phase can arise from the expression of E1A in a similar fashion. Indeed, 
one of its key functions is to disrupt the pRb-E2F interactions, thereby releasing E2F 
transcription factors to activate the E2F responsive promoters and transcription of the 
genes they control. Two conserved regions (CR1 and CR2) in the E1A have been shown 
to act in the disruption of the pRb-E2F complex (Raychaudhuri et al. 1991). CR2 forms a 
strong interaction with the pocket binding domain of pRb and CR1 mediates the actual 
disruption of the E2F binding of pRb (Fattaey et al. 1993).  
Conditionally replicating viruses featuring a 24 basepair deletion in the CR2 were 
created and shown to be potent and selective in the treatment of glioma and breast cancer 
xenografts (Fueyo et al. 2000; Heise et al. 2000). Their cancer specificity results from the 
inability of dysfunctional E1A to release E2F1 transcription factor, which leads to the 
requirement of free E2F1. E2F1 is abundant in cancer cells, where the pRb pathway is 
most often disrupted (Hanahan and Weinberg 2000). This replication control approach has 
gained wide interest in the research field during the last decade, and many vectors studied 
in pre-clinical context feature this deletion. 
3.3.2 Tissue and tumor specific promoters 
Heterologous cellular promoters with different targeting principles have been employed to 
target adenoviral gene transcription and subsequent DNA replication to tumors 
(Nettelbeck 2008). In oncolytic adenoviruses promoters are often utilized to control the 
expression of E1A, the first gene to be transcribed in an infected cell. Furthermore, when 
cellular promoters are used to drive the expression of essential adenoviral genes, the 
corresponding viral regulatory sequences are replaced to get rid of inherent activation of 
viral gene expression. Tissue specific promoters limit the transcription to tumors, but 
retain the ability to function in the healthy tissue of tumor origin as well, thus perhaps 
demanding further means for transcriptional regulation.  
Human α-Lactalbumin (ala) (Li et al. 2005), cyclo-oxygenase 2 (Cox-2) (Bauerschmitz 
et al. 2006) and prostate specific antigen (PSA) promoter (Rodriguez et al. 1997) are tissue 
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specific promoters that have been used to transcriptionally target oncolytic adenoviruses to 
tumors. α-Lactalbumin is produced in differentiated breast epithelial cells and is expressed 
in over 60% of breast cancer tissues (Lee et al. 1984). Its expression is low in virgin 
mammary glands, but rises sharply during pregnancy and in tumors (Li et al. 2005). Cox-2 
is closely linked to carcinogenesis and progression of epithelial tumors (Cao and Prescott 
2002), and is consequently overexpressed in ovarian carcinoma, colorectal cancer, as well 
as prostate cancer with metastatic potential, to name a few (Ali-Fehmi et al. 2003; 
Richardsen et al. ; Wang and Dubois). PSA is produced in prostate cancer cells and, to a 
lesser extent, in prostate ductal epithelia as well as in very small amounts in periurethal 
glands (Aumuller et al. 1990). A rising serum level of PSA is indicative of prostate disease 
and is used as a diagnostic marker. The first tissue specific promoter driven oncolytic 
adenovirus, CN706, featured a PSA promoter controlling E1A (Rodriguez et al. 1997). In 
addition to the PSA core promoter, it now seems that for true tissue-specific expression an 
upstream enhancer is required (Latham et al. 2000).  
Some promoters show high tumor specificity, thereby limiting harmful effects towards 
the healthy tissue of tumor origin. Tumor-type specific promoters show high selectivity 
for a certain tumor type. The downside to their use is their limited applicability for other 
cancer types. Such a promoter is the α-fetoprotein (AFP) promoter: the expression of AFP 
is mainly controlled on the transcriptional level and its promoter is active in fetal liver, but 
is silenced after birth and remains silent throughout life, except in hepatocellular 
carcinoma (HCC) tumors, where it is re-activated (Hallenbeck et al. 1999).  
3.3.3 Pan-cancer promoters 
Pan-cancer promoters target hallmark cancer pathways making them broadly applicable 
for targeting approaches in various cancer types (Nettelbeck 2008). Examples of such 
promoters are E2F1, the human telomerase reverse transcriptase (hTERT) promoter, and 
the multidrug resistance promoter (Mdr1).  
The ends of human chromosomes are organized into telomeres, G-rich tandem repeats 
and associated proteins, which protect chromosomes from end-to-end fusions and 
degradation (Blackburn 1991). In normal cells, telomeres progressively shorten during cell 
divisions. Shortened telomeres act as a senescence signal, leading to growth arrest and 
apoptosis. In contrast, telomeres of cancer cells are maintained due to the activation of 
telomerase enzyme. hTERT is the catalytic rate-limiting subunit of telomerase (Horikawa 
et al. 1999) and its expression is highly specific to cancer cells, while the other telomerase 
subunits are also constitutively expressed in normal cells (Kyo et al. 2008). High 
telomerase activity is observed in over 90% of human cancers and the hTERT promoter is 
upregulated in cancer cells, but repressed in normal cells (Horikawa et al. 1999; Takakura 
et al. 1999). The hTERT promoter is also tightly regulated on the transcriptional level 
(Kyo et al. 2008). Modest telomerase activity is observed in proliferative normal tissues 
with high renewal potential, such as bone marrow (Yui et al. 1998), skin, the 
gastrointestinal tract, testis, and activated lymphocytes (Kyo et al. 2008), a fact that may 
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call for further regulation of hTERT controlled transcription in the context of oncolytic 
adenoviruses. 
E2F transcription factors regulate the expression of a diverse set of genes involved in 
key cellular events by binding to their promoters (Johnson and Schneider-Broussard 1998; 
Muller and Helin 2000). As previously described, the pRb/E2F-1 complex inactivates the 
E2F1 promoter and E2F1 promoter activation requires free E2F1 transcription factor. The 
pRb pathway is disrupted in nearly all human cancers, creating a broad target spectrum for 
E2F1 promoter usage (Hanahan and Weinberg 2000; Johnson et al. 2002).  
The multidrug resistance (Mdr) phenotype is a major cause of cancer chemotherapy 
failure and is mainly due to the overexpression or amplification of the Mdr1 gene 
encoding p-glycoprotein (Pgp) (Labialle et al. 2002). The mdr phenotype is characterized 
by a decrease in the intracellular accumulation of drugs due to energy-dependent drug 
efflux by Pgp. Mdr1 promoter activation is complex, but involves several activation 
elements that have been reported as tumor inducers, such as TCF elements, or enhancer 
elements responsive distress, such as SXR element that is responsive for several 
xenobiotics (Roose and Clevers 1999; Synold et al. 2001). The mdr1 promoter is activated 
in several cancer types. 
3.3.4 Inducible promoters 
Promoters of radiation-inducible genes may be utilized to drive transcription of key viral 
genes in response to ionizing radiation (Mezhir et al. 2006). Such a radiation-inducible 
gene is the early growth response gene 1 (EGR1), which is induced through distal CArG-
elements (Datta et al. 1992). Furthermore, promoters may respond to genotoxic stress such 
as chemotherapeutics, a characteristic that to some extent can be exploited for replication 
control, albeit with requirements for other constrictions on replication (Ciribilli et al. 
2010).  
One useful system for replication control is the tetracycline-derived “Tet-system”, 
which exists in two opposite configurations, the “Tet-Off” and “Tet-On” (Gossen and 
Bujard 1992). In the Tet-Off system, addition of tetracycline represses gene expression, 
while and in the Tet-On system it triggers gene expression. Tet-system has been used to 
control adenoviral replication (Fender et al. 2002). 
Other inducible promoter systems include the heat shock protein promoter 
(Schweinfest et al. 1998), metallothionine regulatory promoter (Hu and Davidson 1990), 
and steroid regulatory promoters (Ko et al. 1989). These systems, however,  have been 
shown to suffer from various limitations, such as leakiness, low expression levels, and 
toxicity of the inducing agents (Yarranton 1992). Therefore, their use with replicating 
adenoviruses would require further optimization. 
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3.4 Controlling replication with pharmaceutical agents 
Adenoviruses do not inherently contain a mechanism for replication inactivation. 
Therefore, external compounds that could be introduced to inhibit viral replication may 
prove useful in case of adverse effects in patients. This negative control over adenoviral 
replication is referred to as a safety switch system. 
Presently, no formally approved compounds are available to treat adenoviral 
infections. Albeit a number of compounds, mostly nucleotide or nucleoside analogues that 
target the adenoviral DNA polymerase, with in vitro and in vivo activity have been 
described. Cidofovir is an acyclic nucleoside phosphonate that acts as an alternative 
substrate for viral DNA polymerase, inhibiting adenoviral DNA replication (Naesens et al. 
2005). Antiviral selectivity results from the higher affinity for viral DNA polymerase. 
Ribavirin is another nucleoside analogue with a controversial mechanism of action and 
perhaps less potency against adenoviruses, as the in vitro susceptibility of adenoviruses to 
Ribavirin has been suggested to be restricted to species C Ads (Morfin et al. 2005). The 
“off-label” use of Ribavirin and Cidofovir as anti-adenoviral therapeutic modalities in 
immunocompromized patients is common, though a number of studies show ambiguous 
results especially with Ribavirin (Lenaerts et al. 2008). Furthermore, resistance to 
Cidofovir has been reported (Kodama et al. 1996). 
Dietary flavonoids are a subject of great interest for their potential use in cancer 
treatment. Interestingly, they are also proposed to possess antiviral activity (Andres et al. 
2009). Guercetin, a flavonoid found in most edible fruits and vegetables, was shown to 
inhibit adenoviral replication at the early stage of infection rather than to inhibit viral 
internalization (Chiang et al. 2003). Soy plants are a rich source of flavonoids. Apigenin, 
another bioflavonoid found in parsley, has been shown to have antiviral activity (Chiang 
et al. 2005). Apigenin induces G2/M phase cell cycle arrest and reduces the levels of 
cyclins (Ujiki et al. 2006; Meeran and Katiyar 2008). Cells arrested in G2/M will not go 
into mitosis and subsequently will not undergo S-phase induction either, which is 
deleterious for adenoviral replication. 
Chlorpromazine is an antipsychotic drug believed to inhibit clathrin-coated pit 
formation by reversibly translocating clathrin and its adapters from the plasma membrane 
to intracellular vesicles (Vercauteren et al. 2010). Adenoviruses enter cells through 
clathrin coated pits and therefore inhibition of their formation inhibits adenoviral 
trafficking and replication. Recently, it was shown, that chlorpromazine exerted its effect 
downstream from nuclear delivery (Diaconu et al. 2010), suggesting that some of its 
various other functions are actually responsible for the inhibition of viral replication 
instead of its action on chlatrin coated pits (Day and Dimattina 1977). The steroidal 
compounds dehydroepiandrosterone (DHEA) and epiandrosterone (EA) exhibit a wide 
range of biologic activities including antiviral actions (Romanutti et al. 2010). They have 
been shown to adversely affect adenoviral protein synthesis and the formation of mature 
viral particles. 
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4 Oncolytic adenoviruses in clinical trials 
Type I oncolytic adenoviruses feature short genetic deletions for transcriptional and 
subsequent replication control purposes. This approach takes advantage of the similarity of 
reguirements of carcinogenesis and DNA virus replication. Usually these deletions are in 
the E1A or E1B adenoviral genes, leading to mutated proteins unable to fulfill functions 
required for viral replication in normal cells but not in cancer cells that represent genetic 
alterations in cellular regulatory pathways. Type II oncolytic adenoviruses feature control 
over replication with various tumor specific promoters (TSP) introduced to regulate 
transcription of adenoviral key regulatory genes, most often E1A, with or without short 
genetic deletions. This mode of control requires replacement of viral promoters, as well as 
activity of the TSP in target tissue. 
ONYX-015 is the first and most studied type I oncolytic adenovirus that has been the 
subject of numerous clinical trials starting from 1996 (for more detailed description of the 
virus see chapter 3.2.1 and for a list of selected clinical trials with oncolytic adenoviruses 
see table 1) (Bischoff et al. 1996). The general strategy utilized for ONYX-015 has been 
to progressively demonstrate safety with various routes of administration: intratumoral 
injections were followed by intraperitoneal administration, intra-arterial infusion, and 
finally intravenous administration (Aghi and Martuza 2005). Initially, ONYX-015 was 
studied in head and neck carcinomas that often result in death due to local disease and 
have accessible tumors for intratumoral injections (Ganly et al. 2000). Intra-arterial 
delivery of ONYX-015 for metastatic colorectal cancer demonstrated oncolytic viral 
replication in patients for the first time (Reid et al. 2001). Finally, doses up to 2 x 1012 
viral particles were shown to be safe with no dose-limiting toxicity (Nemunaitis et al. 
2001). When the safety of ONYX-015 as a single treatment modality was demonstrated in 
various clinical trials, ONYX-015 underwent clinical trials of combination treatment with 
chemotherapeutics (Khuri et al. 2000). In head and neck cancer patients the response rate 
to ONYX-015 treatment in combination with cisplatin and 5-FU was encouraging with 
several patients having 50 % or more reduction in tumor size and some featuring even a 
complete response. Disappointingly, long-term survival did not improve (Alemany 2007). 
Overall, the safety of ONYX-015 was demonstrated in various cancers and with various 
routes of administration. The clinical data, however, seems to point to the need for more 
potent viruses. 
H101 is a very similar virus to ONYX-015, except that it lacks all E3 proteins, 
including ADP, rendering it less potent and more immunogenic. The first stage III trial 
with oncolytic viruses was concluded with H101, where a combination of intratumoral 
H101 with cisplatin and 5-FU resulted in doubled response rates compared to 
chemotherapeutics alone in patients with head and neck tumors (Xia et al. 2004). Survival 
data was inconclusive (Alemany 2007). 
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Table 1. Selected clinical trials with oncolytic adenoviruses 
virus, 
combination 
treatment 
 
genetic 
modification 
 
 
Phase  
/number 
of 
patients 
Cancer 
 
 
 
inject. 
route 
 
 
Results 
 
 
 
Ref. 
 
 
 
ONYX-015 
 
E1B-55K 
deletion1 
I / 22 
 
SCCHN 
 
i.t. 
 
1x1011 pfu 
3 PR, 2 MR 
(Ganly et al. 
2000) 
ONYX-015 
 
E1B-55K 
deletion1 
I /23 
 
pancreatic 
cancer 
i.t. 
 
1x1011 pfu 
no responses 
Mulvihill et 
al. 2001 
ONYX-015 
 
E1B-55K 
deletion1 
I / 10 
 
metastatic 
solid tumor 
i.v. 
 
2x1013 VP 
no responses 
(Nemunaitis 
et al. 2001) 
ONYX-015 
 
E1B-55K 
deletion1 
I / 16 
 
ovarian 
carcinoma 
i.p. 
 
1x1011 pfu/day 
for 5 d 
(Vasey et al. 
2002) 
ONYX-015, 
5-FU, 
cisplatin 
E1B-55K 
deletion1 
II / 37 
 
 
SCCHN 
 
 
i.t. 
 
 
1x1010 pfu/day for 
5 d, 8 CR, 11 PR 
(Khuri et al. 
2000) 
 
ONYX-015, 
5-FU, 
leukovorin 
E1B-55K 
deletion1 
I-II / 11 
 
 
metastatic 
colorectal 
cancer 
i.ha 
 
 
2x1012 VP 
2 PR 
 
(Reid et al. 
2002) 
 
ONYX-015 
 
E1B-55K 
deletion1 
II / 14 
 
SCCHN 
 
i.t. 
 
1x1010 pfu/day for 
5 d, 3 CR, 3 PR 
(Lamont et 
al. 2000) 
ONYX-015 
 
 
E1B-55K 
deletion1 
II / 37 
 
 
SCCHN 
 
 
i.t. 
 
 
2x1011 VP 
twice/day for 10 
days, 3 CR, 2 PR 
(Nemunaitis 
et al. 2000) 
 
H101, 
5-FU,  
cisplatin or 
adriamycin 
 
E1B-55K 
deletion1, 
deletion of E3  
III / 123 
 
 
 
 
SCCHN 
 
 
 
 
i.t. 
 
 
 
 
1.5x1012 VP 
daily for 5 d, 79% 
response in 
combination 
treatment 
(Xia et al. 
2004) 
 
 
 
CV706 
 
 
PSA promoter 
contolling E1A 
I / 20 
 
 
prostate 
cancer 
 
i.t. 
 
 
1 x 1013 pfu, 
transient decrease 
in PSA levels 
(DeWeese et 
al. 2001) 
 
CG7870 
 
 
 
 
rat probasin 
promoter 
contolling E1A, 
PSA promoter 
contolling E1B 
I / 23 
 
 
 
 
prostate 
cancer 
 
 
 
i.v. 
 
 
 
 
6 x 1012 VP, 25%-
49% decrease in 
serum levels of 5 
patients 
(Small et al. 
2006) 
 
1Two deletions in the E1B-55K adenovirus gene  
Abbreviations: SCCHN, squamous cell carcinoma of the head and neck; HCC, hepatocellular carcinoma ; i.t. 
intratumoral; i.v. intravenous; i.p. intraperitoneal; i.ha., intrahepatic artery; 5-FU, 5-fluorouracil; pfu, plaque 
forming units; VP, viral particles; CR, complete response; PR, partial response; MR, minor response; d, days 
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CV706 was the first Type II oncolytic adenovirus created and studied in clinical trials 
(Rodriguez et al. 1997). It contains the PSA promoter and enhancer to drive E1A 
expression. In a phase I trial for locally recurrent prostate cancer, CV706 was well 
tolerated with mild side effects in response to intratumoral injection of 1 x 1013 pfu 
(DeWeese et al. 2001). In subsequent studies, improvements to CV706 were introduced  
with a final construct, CG7870, containing the rat probasin promoter in addition to the 
PSA promoter and demonstrating good safety in intravenous delivery (Small et al. 2006). 
Unfortunately, the PSA levels only transiently decreased. 
5 Other oncolytic viruses 
Other naturally oncolytic viruses or viruses genetically rendered oncolytic include the 
herpesviruses (HSV), influenza virus (IV), Newcastle disease virus (NDV), parvoviruses, 
poxviruses, reovirus, vesicular stomatitis virus (VSV), and Vaccinia virus (Sinkovics and 
Horvath 2008). Some of these viruses and their use in cancer therapy is discussed briefly. 
Herpes simplex virus (HSV)-1 has a natural tropism for neuronal tissue, and is thus 
suitable for treating brain tumors such as glioblastoma (Grandi et al. 2009). HSV genes 
are classified as essential or nonessential based on their requirement for virus replication. 
Nonessential viral functions are manipulated to create oncolytic HSV-1 -vectors 
(Varghese and Rabkin 2002). HSV-1 can establish a latent infection in sensory neurons, or 
a lytic cycle in cells permissive for replication. Oncolytic HSV-1 vectors are genetically 
modified so that they can establish a lytic cycle only in cancer cells that either lack cellular 
functions that normally inhibit mutant virus replication or express high amounts of 
specific proteins that support replication. HSV-1 is a highly infectious virus and its 
replication leads to rapid cell death and release of new virus particles upon cell lysis. Four 
distinct HSV-1 vectors G207, 1716, NV1020 and OncoVEXGM-CSF have been studied in 
clinical trials for glioma, melanoma, and metastatic colorectal cancer (Markert et al. 2000; 
Rampling et al. 2000; MacKie et al. 2001; Senzer et al. 2009). Studies confirmed the 
safety of intratumoral and intralesional injections and a maximum dose of 1.3 x 107 pfu 
was tolerated in i.ha injections. Two patients with recurrent glioma treated with G207 
intratumorally lived for over 4 years, suggesting therapeutic benefit (Markert et al. 2000). 
OncoVEXGM-CSF is a selectively replicating HSV-1 encoding GM-CSF for immune 
response enhancement (Liu et al. 2003). In a phase II trial of nonresectable metastatic 
melanoma, 50 patients received median of 6 intratumoral injections of up to 4 x 108 pfu  
OncoVEXGM-CSF (Senzer et al. 2009). Eight patients showed complete response, five 
patients displayed stable disease, and regression of both injected and distant lesions 
occurred. Overall survival was impressive, 52 % at 24 months. 
Newcastle disease virus (NDV) causes Newcastle disease in birds, but has been 
demonstrated to selectively replicate in and kill human tumor cells sparing normal cells 
(Reichard et al. 1992). NDVs have been classified as lytic or non-lytic strains. Lytic 
strains cause lysis of target mammalian cells by inducing changes in the plasma membrane 
(Pecora et al. 2002), and non-lytic strains cause slow tumor regression by disrupting 
normal host cell metabolism (Schirrmacher et al. 1999). Furthermore, non-lytic strains can 
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enhance immune responses against infected tumors by inserting viral proteins on to tumor 
cell membranes or by inducing the host to produce effector cytokines in response to the 
virus itself, thereby eliciting NDV-specific immune response that results in NK, 
macrophage, and T-cell responses against infected cells (Schirrmacher et al. 2001). The 
most widely studied strain, Ulster, is a non-lytic strain, but lytic strains have also been 
studied as anti-cancer agents (Ravindra et al. 2009). The first clinical trial (stage II) for 
NDV was conducted in 1975 in patients with stage III melanoma metastasized to regional 
lymph nodes (Cassel and Murray 1992). Patients received a post-surgery adjuvant vaccine 
composed of allogeneic and autologous human melanoma cells infected with live NDV. 
This trial was not  prospectively randomized, and therefore the results should be viewed 
with caution; nevertheless, when compared to contemporary worldwide control patients 
with stage III melanoma that experience a high relapse rate of 70-80%, a relapse rate of 
less than 20% of NDV-lysate treated patients in 10 years was encouraging (Batliwalla et 
al. 1998; Sinkovics and Horvath 2008). 
Vaccinia virus from the family Poxviridae had a crucial role in the eradication of 
smallpox (Fenner 1980). Its use as a smallpox vaccination has led to a better 
understanding of its biology and pathogenesis as well as knowledge of which populations 
may be at risk for rare adverse events (Enserink 2002). Vaccinia virus replicates and lyses 
cells rapidly, which is of great importance in terms of efficacy (Wein et al. 2003). Second, 
they do not require specific cellular receptors for entry – instead, they infect target cells 
through several membrane fusion pathways and thereby feature broad tumor tissue 
tropism (Moss 2006). Third, vaccinia are produced in several antigenic forms in which the 
enveloped virus (EEV) has a host cell-derived envelope with only a few exposed viral 
proteins, resulting in efficient spread within the host blood stream without immune 
defence mechanisms recognizing it (Vanderplasschen et al. 1998). Vaccinia viruses can 
selectively replicate in and lyse cancer cells due to their natural biology and through 
genetic engineering of viral transformation genes that in a normal situation make normal 
cells susceptible to viral replication. One targeted and armed oncolytic vaccinia virus, 
JX-594, has entered clinical trials (Mastrangelo et al. 1999). JX-594 is a Wyeth strain 
vaccinia featuring an inactivated thymidine kinase gene and a GM-CSF transgene under a 
synthetic promoter. In a pilot phase I study of melanoma, intratumoral injections of 
JX-594 resulted in 71% tumor response. Furthermore, a response in distant skin 
metastases was also witnessed. In a phase I-II dose escalation study patients with 
advanced melanoma or hepatocellular, colorectal, or lung cancer received four 
intratumoral injections of JX-594 every 3 weeks. The virus was well tolerated up to 1 x 
109 pfu, and efficacy was shown in diverse tumor types, at both injected and non-injected 
sites (Park et al. 2008). Seven patients out of ten patients available for evaluation had 
stable disease. Furthermore, the presence and replication of JX-594 in non-injected tumor 
sites was witnessed. 
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6 Xenograft murine tumor models for cancer 
The preclinical models predominantly used for cancer research are various murine 
xenograft transplant models, where in vitro cultured human cancer cells are transplanted 
into immunocompromised mice. Various injection sites are utilized and termed xenograft 
transplantation, notably intravenous, intraperitoneal, subcutaneous, and orthotopic 
injections (Kim and Baek 2010). Xenograft tumors are easily replicated, which facilitates 
the reliability of research results, as the baseline material is comparative. Subcutaneously 
growing tumors are easy to monitor physically, and various marker genes such as GFP and 
luciferin may be utilized to allow non-invasive monitoring of tumor growth, when the 
cancer cells express these markers. Human origin of the tumors is also important for 
cancer research, and the possibility of tumor metastasis in xenograft models creates an 
opportunity to study the metastatic potential and behaviour of cancer. Unfortunately, 
various disadvantages exist. Firstly, an immunocompromised host is necessary in 
xenograft models (Frijhoff et al. 2004). This is a serious drawback, especially when 
investigating the systemic behavior of highly immunogenic agents, such as adenoviruses, 
in a cancer model. Secondly, tumors are growing in host stroma instead of endogenous 
stroma, probably effecting tumor development in xenograft models. Crosstalk between 
different cell types within a tumor and the stroma surrounding it is recognized as an 
important factor in tumor development (Mueller and Fusenig 2004). Furthermore, 
xenograft models usually require transplantation of large numbers of cells for tumor to 
develop, and the tumor development is often rapid, with a latency period of only days to 
weeks. A very different situation exists in a cancer patient, where a tumor may develop for 
even years. Also, in vitro culturing of cells prior to transplantation results in selection of 
cells displaying such properties that may differ from the properties of the initial tumor 
cells. 
One of the major drawbacks of using any kind of murine models in adenoviral gene 
therapy research relates to the inability of adenoviruses to replicate in murine tissue. Both 
normal and cancerous mouse tissue are poorly permissive for adenoviral replication 
(Duncan et al. 1978; Ginsberg et al. 1991).  
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AIMS OF THE STUDY 
1. To evaluate the effect of capsid modifications and Kupffer cell depleting agents on 
gene transfer efficacy and oncolytic potency of genetically engineered 
adenoviruses in breast cancer cell lines, tissues and murine models (I, II). 
 
2. To construct Ad5.pK7-Δ24, a replicating oncolytic adenovirus with expanded 
tropism and selectivity for the pRb pathway defective cells (I).  
 
3. To evaluate oncolytic potency of transcriptionally regulated oncolytic adenoviruses 
on CD44+ CD24-/LOW putative cancer stem cell populations derived from pleural 
effusions of breast cancer patients (III). 
 
4. To develop murine models for breast cancer that can be imaged noninvasively for 
tumor progression (I, II). 
 
5. To evaluate the use of pharmaceuticals as a means of adenoviral replication 
reduction in case of replication associated side effects in patients (IV). 
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MATERIALS AND METHODS 
1 Cell lines and fresh human tissues 
Cell lines (listed in Table 2) used in this study were cultured in the growth medium 
recommended by the supplier, supplemented with 10% fetal calf serum (FCS), 2 mM 
L-glutamine, and penicillin-streptomycin. Cells were maintained in a humidified 
atmosphere at 37°C and 5% CO2. 
 
Table 2. Human cell lines used in this study. 
cell line Description Source Study 
293 transformed embryonic kidney cells ATCC1 I-IV 
911 transformed human embryonic retinoblasts Dr Van Der Eb2 III 
A549 lung adenocarcinoma ATCC1 I-IV 
MDA-MB-435 breast ductal carcinoma, derived from pleural 
effusion  
ATCC1 I, II 
MDA-MB-436 breast adenocarcinoma, derived from pleural 
effusion 
ATCC1 I, II 
M4A4-LM3 a metastatic derivative of MDA-MB-435, 
stably transfected with GFP 
Dr S. Goodison2 I, II 
ZR-75-1 breast ductal carcinoma, derived from ascites ATCC1 I, II 
MCF7 breast adenocarcinoma, derived from pleural 
effusion 
ATCC1 I, II 
CAMA-1 brest adenocarcinoma ATCC1 I, II 
JIMT-1 breast ductal carcinoma, derived from pleural 
effusion 
Dr J. Isola 3 III 
Hey Ovarian adenocarcinoma Dr J. Wolf 4 IV 
Ov-4 Ovarian adenocarcinoma Dr T.J. Eberlein 5 IV 
1Cell line purchased from American Type Culture Collection (ATCC) 
2Departments of Molecular Cell Biology and Surgery, Leiden University Medical Center, Leiden, The 
Netherlands 
3 University of Florida, Jacksonville, FL, USA 
4cell line is a gift from Dr. Minna Tanner (University of Tampere and Tampere University Hospital, 
Tampere, Finland) 
5M. D. Anderson Cancer Center, Houston, TX, USA 
6Harvard Medical School, Boston, MA, USA 
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2 Adenoviruses 
Table 3. Recombinant adenoviruses used in this study. 
virus E1 region status targeting motif study reference 
Ad5 (GL) 
 
GFP, luciferase 
 
- 
 
I, II 
 
(Wu et al.  
2002) 
Ad5.LacZ 
 
β-galactosidase 
 
- 
 
II 
 
(Yotnda et al.  
2004) 
Ad5lucI 
 
luciferase 
 
- 
 
II 
 
(Kanerva et al.  
2002) 
Ad5/3lucI 
 
luciferase 
 
5/3 serotype chimera 
 
II, III 
 
(Kanerva et al.  
2002) 
Ad5lucRGD 
 
luciferase 
 
RGD 
 
II 
 
(Dmitriev et al.  
1998) 
Ad5.pK7(GL) 
 
GFP, luciferase 
 
polylysine 
 
I, II 
 
(Wu et al.  
2002) 
Ad5.RGD.pK7(GL) 
 
GFP, luciferase 
 
polylysine, RGD 
 
II 
 
(Wu et al.  
2002) 
Ad5/3mdr-E12 
 
multidrugresistance promoter 
 
5/3 serotype chimera 
 
III 
 
(Bauerschmitz et al.  
2008) 
Ad5Δ24E3 
 
Δ241 
 
- 
 
I, II 
 
(Suzuki et al.  
2001) 
Ad5/3-Δ24 
 
Δ241 
 
5/3 serotype chimera 
 
II-IV 
 
(Kanerva et al.  
2003) 
Ad5-Δ24RGD 
 
Δ241 
 
RGD 
 
II 
 
(Fueyo et al.  
2000) 
Ad5.pK7-Δ242 
 
Δ241 
 
polylysine 
 
I, II 
 
(Ranki et al.  
2007) 
Ad5/3ala-Δ242 
 
α-lactalbumin promoter, Δ241 
 
5/3 serotype chimera 
 
III 
 
(Bauerschmitz et al.  
2008) 
Ad5/3mdr-Δ242 
 
Δ241, multidrug resistane 
 promoter 
5/3 serotype chimera 
 
III 
 
(Bauerschmitz et al.  
2008) 
Ad5/3-hTERT-Δgp2 
 
Δ241, hTERT promoter 
 
5/3 serotype chimera 
 
III 
 
(Bauerschmitz et al.  
2008) 
Ad5/3-Cox2L-Δ242 
 
Δ241, Cox-2 promoter 
 
5/3 serotype chimera 
 
III 
 
(Bauerschmitz et al. 
 2008) 
1 24 base pair deletion in the E1A CR2 that targets viral replication to cells with defective pRb pathway 
2 Viruses constructed in the context of this thesis. 
 
An informed consent from patients and permission for studies on human tissue from the 
ethics committee was obtained prior to any experiments. Breast cancer samples were 
obtained from patients undergoing surgery and fresh liver samples were obtained from 
healthy donor livers that were to be implanted into recipients, both by the Department of 
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Surgery, Helsinki University Hospital. Livers were kept on ice in ViaSpan solution 
(Bristol-Myers Squibb Ab, Bromma, Sweden) until slicing. Precision-cut slices (250µm) 
were cut with a Vibratome 1000 plus sectioning system (Vibratome, St Louis, MO, USA) 
and cultured on a rocker in the same conditions as cell lines. Oxygenated William´s 
medium E with 25 mM D-glucose and 50 µg/ml was used as a growth medium. 
Ad5.pK7-∆24 (I) was constructed by co-transfecting (Effectene Transfection Reagent, 
Qiagen Corporation, Hilden, Germany) ethanol precipitated Ad5.pK7 (GL) DNA (Wu et 
al. 2002) with PacI and PmeI digested pShuttle∆24 (Fueyo et al. 2000) plasmid DNA in a 
1:1 weight to weight ratio into 293 cells. Individual plaques were collected and purified 
for 2 rounds on A549 cells.  
Ad5/3ala-d24, Ad5/3mdr-E1 and Ad5/3mdr-d24 (III) were constructed by cutting 
promoter sequences from pGL3-ALA (Li et al. 2005) and pM3mdr-p-hTNF (Walther et al. 
1997) into pSE1 and pSE1d24 (Nettelbeck et al. 2002), from which the E1 promoter was 
removed. The viral backbone was rescued in 911 cells with PacI digested pTU-5/3 (Uil et 
al. 2003). For construction of Ad5/3-hTERT-Δgp, the hTERT was cloned into pSE1 
(Nettelbeck et al. 2002), resulting in pShTERTE1. pAd5/3-hTERT-E1-Δgp was generated 
by homologous recombination in BJ5183 cells using PmeI digested pShTERTE1 and SrfI 
linearized pAdEasy-1.5/3-Δgp (serotype 3 knob, a 24 bp deletion in E1A and a 965 bp 
6.7K/gp19K deletion in E3A) for transfection into 911 cells. The same promoter sequences 
were cloned to replace CMV in pShuttle-CMV (AdEasy, QBiogene, Carlsbad, CA) and 
luciferase was cut from pGL3-Basic (Promega, Madison, WI) for homologous 
recombination with pAdEasy-1 to create non replicating control viruses.  
All replicating viruses were produced in A549 cells and nonreplicating viruses on 293 
cells. Viruses were purified on double CsCl gradients using standard methods.The viruses 
were titered for viral particles (VP) at 260 nm. The functional titer was determined with 
the plaque assay or TCID50 assay of 293 cells for nonreplicating viruses and A549 cells 
for replicating viruses. The modified region on the genome were confirmed by sequencing 
and polymerase chain reaction (PCR) with appropriate primers.  
All recombinant viruses used in this study are listed in table 3 with the appropriate 
references mentioned for those viruses that we did not create.  
3 In vitro experiments 
3.1 Gene transfer assays 
Gene transfer assays were done for various fiber modified (I, II) and transcriptionally 
controlled (III) non-replicating Ads in order to evaluate the effect of a particular fiber 
modification on transductional efficacy of the virus or the effect of a particular promoter 
on gene expression. Assays were performed in various breast cancer cell lines (I,II), 
JIMT-1 cell line sorted for CD44+/CD24-/LOW expression (III), and fresh breast cancer 
tissue (II). Luciferase activity was analyzed and the results were depicted as relative to a 
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control virus. Protein content was measured when analyzing patient samples and used as 
an internal control. For more detailed protocols, see “Materials and Methods” from the 
respective articles. 
3.2 Cytotoxicity assay (I-IV) 
To study the cell killing efficacy of oncolytic viruses, cells were infected with three 
virus doses and followed for the cytopathic effect. Cell viability was measured with an 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay when one of the viruses had reached complete cell killing with the 
highest amount and significant cell killing with the second highest virus amount. MTS 
assay is a non-radioactive cell proliferation assay where tetrazolium compound (MTS) is 
reduced by cells into formazan. The amount of formazan is measured by absorbance in 
492 nm.  
The length of the experiment for each cell line was internally timed for maximum 
dynamic range with the positive and negative controls. When assessing the effect of 
apigenin and chlorpromazine on replication, these compounds were applied to the cells 
prior to infection. For more detailed protocols, see “Materials and Methods” from the 
respective articles (I-IV).  
3.3 Quantitation of viral replication (IV) 
The effect of apigenin and chlorpromazine on viral replication was assessed by 
quantitating viral replication in ovarian carcinoma cell lines or liver tissue after first 
preincubating the samples with the compounds. Infected cells and liver slices were 
collected at different time points and freeze thawed to release the viruses. The supernatant 
was subsequently used to analyze replication with TCID50 on 293 cells. Results were 
compared to samples without chlorpromazine or apigenin preincubation and mock treated 
cells.  
Furthermore, liver aspartate transaminase (AST) levels were analyzed with a 
photometric method from the supernatant of infected liver slices. For more detailed 
protocols, see “Materials and Methods” from the respective article (IV).  
3.4 Isolating CD44+ CD24-/LOW cell population (III) 
Cells from pleural effusion samples and JIMT-1 cell line were sorted with 
FITC-labeled anti-CD44 and phycoerythrin-labeled anti-CD24 antibodies and collected 
with magnetic beads (III). 
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3.5 Comparison of receptor levels in vitro (I) 
To study the CAR and HSPG levels in the M4A4-LM3 cell line, trypsin-EDTA 
preincubated cells were labeled with the anti-CAR primary antibody RmcB or anti-HSPG 
primary antibody 10E4. A phycoerythrin-labeled goat anti-mouse antibody was used as a 
secondary antibody, and labeled cells were analyzed with flow cytometry. For more 
detailed protocols, see “Materials and Methods” from the respective article (I). 
4 In vivo experiments 
 
Figure 6. Xenograft murine models utilized in this thesis. A) Systemic treatment model with 
M4A4-LM3 breast cancer cells inoculated with a midaxillary percutaneous injection under the 
sixth rib into the left lung or mediastinum. Tumors were imagable with Xenogen IVIS 100 
imaging system for GFP expression in the cancer cells. Mice were treated with intravenous 
injections. Model was used in study II. B) Orthotopic breast cancer model with M4A4-LM3 cells 
injected into the left and right uppermost mammary fat pad. Tumors were imagable with Xenogen 
IVIS system for GFP or physically measurable with a caliber. Studies I-III. C) Orthotopic ovarian 
cancer model with SKOV3.ip1 cells injected into the peritoneum of SCID mice. Tumors were not 
imagable. Study IV. D) Subcutaneous tumor model with ovarian cancer Hey cells injected into the 
flanks of SCID mice. Tumors were measured physically with a caliber. Study IV. 
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Pathogen free 3 to 4-week-old female NMRI (Naval Medical Research Institute) nude or 
C.B-17 SCID (severe combined immune deficiency) mice were obtained from Taconic 
(Ejby, Denmark) and quarantined for 2 weeks prior to any experiments. All animal 
experiments were performed according to the rules of the Provincial Government of 
Southern Finland. 
4.1  Mouse models of breast and ovarian cancer (I – IV) 
To create an orthotopic breast cancer model, mice were injected into the left and right 
uppermost mammary fat pads with 2 x 106 sorted JIMT-1 cells or GFP expressing 
M4A4-LM3 cells and a tumor was allowed to develop (I-III). The maximum diameter of 
a tumor was 1 cm. To study the metastasis of M4A4-LM3 into lymph nodes, mice were 
euthanized, and axillary lymph nodes were harvested and imaged for GFP expression with 
the Xenogen IVIS 100 imaging system. 
A systemic treatment model mimicking breast cancer lung metastasis was established 
(II). 2 x 106 M4A4-LM3 cells were inoculated with a midaxillary percutaneous injection 
under the sixth rib into the left lung or mediastinum. Mice were imaged as above and 
survival was followed and mice were euthanized when disease related adverse effects 
occurred.  
For a subcutaneous ovarian cancer model 5 x 106 Hey cells were injected into the 
flanks of nude mice and followed for growth with caliber measurements. The maximum 
diameter of a tumor was 1 cm. For an orthotopic ovarian cancer model 1 x 107 SKOV3.ip1 
cells were injected i.p. into SCID mice and a tumor allowed to develop (IV). 
4.2 Noninvasive imaging (I, II) 
M4A4-LM3 cells used in the breast cancer animal models express GFP. 
Nonreplicating viruses used in biodistribution experiments in mice express luciferase. 
Mice were imaged with the Xenogen IVIS 100 imaging system to monitor tumor growth 
in breast cancer animal models or to evaluate viral distribution after intravenous injection. 
Images were obtained with a charge-coupled device camera cooled to -120 C with the 
field of view set to 15 cm. Fluorescence images were obtained with an open GFP 
excitation filter and low level intensity. For bioluminescence images, mice were injected 
intravenously with D-luciferin and after 10 minutes imaged. For more detailed protocol, 
see “Material and Methods” of the respective articles (I, II) 
4.3 Efficacy of replicating viruses in vivo (I-IV) 
To test the effectiveness of replicating viruses in the mammary fat pad model 3 x 108 
VP in 50 µl were injected on 3 subsequent days into approximately 0.5 cm wide tumors 
(I). Tumors were measured daily with a caliber and imaged thrice weekly with the IVIS 
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system. In the systemic treatment model 3 x 1010 VP in 100 µl was injected intravenously 
10 days after injection of cells and again on day 33. Tumors were imaged and measured as 
above starting on day 10. 
To assess antitumor efficacy of various tumor specific promoter driven viruses in 
tumors formed by CD44+CD24-/LOW cell populations, sorted JIMT-1 cells were injected as 
above and tumors were treated with intratumoral virus injections thrice weekly for 5 
weeks (III). Tumor growth was followed throughout the experiment. To further evaluate 
the ability of selected viruses to kill putative CD44+CD24-/LOW cancer stem cells in the 
mammary fat pad model, tumors were analyzed by flow cytometry for CD44 and CD24 
expression after 17 days of treatment. 
To assess efficacy of replicating viruses in the metastatic breast cancer model, mice 
were injected intravenously with 2 x 1010 VP of virus 5 days after cell injections (II). 
Treatments were repeated on days 10, 15, and 20. Mice were noninvasively imaged and 
followed for survival. The effect of kupffer cell depleting polyI on survival was evaluated 
in the same setting. PolyI was injected intranvenously prior to virus injection. The 
treatment scheme was as above and the survival of the mice was monitored accordingly. 
4.4 Biodistribution of adenoviruses (II) 
The orthotopic mammary fat pad model was utilized to study the effect of various capsid 
modifications on viral gene transfer in vivo. 5 x 1010 VP capsid modified nonreplicating 
luciferase expressing viruses were injected intravenously to tumor bearing mice. After 48 
hours the mice were euthanized and their tumors and organs were collected, homogenized 
and analyzed for luciferase expression. The protein content was also measured for each 
sample and used as an internal control. 
4.5 KC depletion (II) 
The effect of KC depleting agents gadolinium chloride (GdCl3), polyinosinic acid (polyI), 
and liposomes on gene transfer efficacy was studied in the orthotopic mammary fat pad 
model. Tumor bearing mice were treated with intravenous injections of the compounds 
prior to injection of 2 x 1010 VP of luciferase expressing virus. Thereafter, analysis of the 
tumors was performed as in the biodistribution study. 
4.6 Inhibition of viral replication (IV) 
To assess the effect of chlorpromazine and apigenin on viral replication in vivo, the 
ovarian cancer model was utilized. Tumors were treated with intratumoral injections of 
virus on days 0, 2, and 4. Mice received daily injections of 200µg chlorpromazine or 
250µg apigenin i.p and tumor volume was followed daily. 
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To assess the effect of apigenin and chlorpromazine on replication, the treatment 
scheme was as above except for a single virus injection on day 0. Tumors were harvested 
at different time points, homogenized and freeze thawed repeatedly to release the viruses 
from cells. The amount of infectious particles was analyzed with TCID50. 
4.7 Murine toxicity model (IV) 
To analyze the effect of chlorpromazine and apigenin on virus related toxicity, the i.p. 
ovarian cancer model was utilized. Ten days after cell injection mice received a single 
virus injection i.p. and the previously described dose of either compound. Thereafter, 
apigenin or chlorpromazine was given daily. Further, mice received 80 mg/kg i.p. on four 
days. Mice were killed when any pain or distress occurred and tumors and livers analyzed 
histologically. 
5 Histopathology and immunohistochemistry (I, IV) 
Livers and tumors were collected in buffered formalin (10 %), embedded in paraffin and 
cut into 5 µm sections.  
Deparaffinized specimens were stained with hematoxylin and eosin to study the 
histopathology of the specimens. Histopathology was scored blinded by an independent 
pathologist. 
Immunohistochemical stainings with anti-CAR primary antibody RmcB or anti-HSPG 
primary antibody 10E4 and phycoerythrin-labeled goat anti-mouse secondary antibody 
were used to study whole-tumor sections for CAR and HSPG expression (I). 
6 Statistical analysis 
The two-tailed student´s t-test was used to analyze the differences in gene transfer efficacy 
between viruses and their control groups as well as to analyze the difference between a 
single time point in the tumor size data (I). Oncolytic cell killing efficacy (MTS test) data 
was analyzed by one-way ANOVA (II). The survival curves were calculated according to 
Kaplan-Meier and groups were compared pairwise with the logrank test (SPSS 11.5) (I, 
II). 
The effects of chlorpromazine and apigenin on viral replication and cell viability were 
analyzed using bootstrap multiple comparisons of means in analysis of variance 
(ANOVA) (PROC MULTTEST SAS v 9.1) to account for multiple testing (IV). For 
statistical analyses the levels of viral replication were log-transformed for normality. 
The analysis of tumor size data was performed using a repeated measures growth 
model with PROC MIXED (SAS v 9.1) (IV). The tumor size data was log-transformed for 
normality. The effects of time, treatment group and interaction between time and treatment 
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group were shown as F-test results. The a priori planned comparisons of differences in 
predicted treatment means were computed by t-statistics on the last time-point and 
averaged over all time points. 
A value of P<0.05 was deemed statistically significant for all studies (I-IV). 
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RESULTS AND DISCUSSION 
1 The effect of capsid modifications and Kupffer cell depletion on 
gene transfer efficacy and oncolytic activity 
Perhaps the most limiting factor in the use of oncolytic adenoviruses for cancer treatment 
is the limited transduction of target cells. The low expression of Ad5 primary receptor 
CAR on tumor cells results in poor transduction efficacy, at least in vitro (Kim et al. 
2002).  Most adenoviral gene therapy approaches are based on utilizing serotype 5 viruses, 
and therefore extensive research efforts have focused on identifying feasible means to 
circumvent CAR dependence. Receptor expression on cell lines obviously plays a major 
role in Ad transduction. Nevertheless, because gene transfer is the most relevant endpoint 
when evaluating the feasibility of different capsid modifications in adenoviral gene 
therapy, we elected to study functional transgene delivery directly instead of receptor 
expression. Furthermore, there are published studies concerning CAR and integrin levels 
on breast cancer cell lines, and our results may be discussed in respect to existing 
knowledge. 
For enhanced gene transfer to cancer cells we chose genetic engineering as the 
adenovirus capsid modification. With oncolytic cell killing being ultimately the means of 
action, it is necessary to retain all modifications in the progeny virions and therefore the 
genetic approach is the only option as the non-genetic bispecific antibody modification 
would be lost upon viral infection. 
1.1 Gene transfer efficacy of capsid modified non-replicating adenoviruses 
to breast cancer cell lines and patient tissue  
Our goal was to evaluate various previously reported capsid modifications for their 
efficacy in gene transfer to gain insight into their performance in breast cancer treatment. 
In other words, we sought to identify the most effective capsid modification in terms of 
gene delivery to breast cancer cells, in order to translate the concept into a replicating, 
oncolytic agent that would be efficient in breast cancer cell oncolysis.  
The fiber knob region is responsible for the binding of the primary receptor CAR, 
which has led to various attempts to retarget adenoviruses through changes in the knob. 
We used viruses with targeting ligands incorporated into the C-terminus or the HI-loop, 
which have previously been reported as feasible locales (Wickham et al. 1993; Krasnykh 
et al. 1998; Borovjagin et al. 2005). Arg-Gly-Asp (RGD) modification in the HI-loop of 
the knob allows the virus to utilize cellular integrins for binding and internalization, 
retaining the CAR binding ability (Dmitriev et al. 1998). Similarly, a polylysine (pK) 
modification in the C-terminus of the knob allows internalization through HSPGs in 
addition to CAR (Wu et al. 2002). These features were also combined in hope of gaining 
additive enhancement of transduction. Importantly, ligand incorporation results in tropism 
expansion, but not true retargeting with CAR binding ablation, whereas serotype chimeric 
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viruses display true de- and retargeting. In addition to viruses featuring targeting ligands, 
we utilized a serotype 3 chimeric Ad5 virus that features a serotype 3 knob domain and 
targets a yet unknown serotype 3 receptor but not CAR (Kanerva et al. 2002). 
Capsid modifications resulted in significant and, in some cases, even dramatic 
increases in gene transfer efficacy in breast cancer cell lines (figure 1a in study I). Gene 
transfer efficacy was evaluated by analyzing the intensity of bioluminescence resulting 
from the luciferin converting activity of luciferase gene that nonreplicating adenoviruses 
express. 
The polylysine modification pK7 displayed superior gene transfer efficacy in all but 
one cell line tested, reaching as high as a 700-fold increase in marker gene expression in 
MDA-MB-435, a ductal carcinoma cell line and in MCF-7, an adenocarcinoma cell line. 
The Ad5/3 chimera displayed the highest gene transfer efficacy in CAMA-1, an 
adenocarcinoma cell line, and a 100-fold increase in ZR-75-1, a ductal carcinoma cell line. 
MDA-MB-435, MCF-7, and ZR-75-1 reportedly display very low levels of the CAR 
receptor, which explains the dramatic increase in gene transfer with capsid modified 
viruses (Lucas et al. 2003). The M4A4-LM3 cell line is a metastatic derivative of MDA-
MB-435 and was shown to express in vitro very low levels of CAR and sufficient levels of 
HSPG, explaining the superiority of pK7 modification (figure 5c in study I). 
The overall gene transfer enhancement was more modest in MDA-MB-436 compared 
to other cell lines, with a 30-fold increase in marker gene expression with the pK7 and 
RGD modified viruses. This cell line has been previously described to feature high CAR 
expression levels, which may partially explain the less pronounced benefit from capsid 
modifications (Lucas et al. 2003). The double-modified Ad5.RGD.pK7 virus featuring 
RGD and pK7 modifications in the HI-loop and C-terminus was generally less effective in 
comparison to single-modified viruses. Double modifications may impose steric hindrance 
that can interfere with receptor recognition and binding, perhaps explaining the rather 
unimpressive performance of double-modified viruses. Furthermore, incorporation of 
ligands imposes structural constraints on the folding and trimerization of the knob 
(Borovjagin et al. 2005), perhaps resulting in a purified prep with less viable double-
modified virions than with single-modified counterparts. 
We analyzed gene transfer efficacy to clinical breast cancer samples from patients with 
advanced disease (all grade 3) (figure 1b in study II). Gene transfer enhancement was 
more modest overall with an approximately 2-7 fold increase with pK7 modification in all 
the samples and a 2-11 fold increase with the chimeric 5/3 capsid in two samples. Neither 
RGD nor pK7.RGD double-modification resulted in increased gene transfer to clinical 
samples. The overall less pronounced increase in gene transfer efficacy compared to that 
seen in cell lines was logical, as the tumor tissue was not homogenized into a single cell 
solution and therefore featured characteristics that would impair viral infectivity. Such 
characteristics would include heterogenous size of the tissue pieces, heterogenous cell 
population within the tissue, and the possible presence of connective tissue, which would 
confer an anatomical barrier to viral infection. The use of nonreplicative viruses only 
allowed infection of the outer layer cells when encountering tissue with a larger volume. 
Kupffer cell depletion with poly(I) prior to viral injection resulted in a 10 fold 
enhancement in gene transfer efficacy to tumors (figure 4A in study II). When we 
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attempted to gain the same effect in combination with viral treatments, however, no signal 
was obtained from the tumors or livers of the mice imaged with xenogen IVIS 100 (figure 
4B in study II). 
In conclusion, capsid-modified viruses displayed significantly enhanced gene transfer 
efficacy to breast cancer cell lines and breast cancer tissues. 
1.2 Biodistribution of capsid modified viruses 
We evaluated the effect of capsid modifications on the biodistribution of viruses after 
intravenous injections to mice bearing mammary fat pad tumors. After intravenous virus 
injection tumor transduction was demonstrated (figure 3c in study II). Most of the marker 
gene expression was seen in the liver, however, which was to be expected as intravenously 
delivered virus usually homes to Kupffer cells and hepatocytes and most of the transgene 
expression is detected from hepatocytes (Vrancken Peeters et al. 1996; Connelly 1999; 
Alemany et al. 2000), and because the capsid modifications were not designed to confer 
any liver detargeting properties. No significant differences were seen in the biodistribution 
profiles between capsid modified and unmodified viruses. Furthermore, no differences 
were seen in the ratio between tumor and liver homing, as all the viruses displayed 
effective liver transduction and less impressive tumor transduction (figure 3f in study II). 
Nevertheless, capsid modified viruses displayed less liver transduction compared to Ad5, 
though no significance due to high variability emerged. For example, the mean marker 
gene expression level from the liver was over 30 times less with RGD-modified virus than 
with Ad5, suggesting a trend towards favorable tumor to liver transduction. Interestingly, 
M4A4-LM3 cell line derived tumors were found to upregulate CAR, a phenomenon that 
would diminish any favorable effects capsid modifications would display in a CAR 
deficient setting often associated with tumors (figure 5 d-f in study I) (Kim et al. 2002). 
A similar phenomenon previously demonstrated in a study where the CAR level and 
location were different when the same breast cancer cells were grown on plates versus in a 
three-dimensional model system (Anders et al. 2003). Furthermore, with brain tumors it 
was demonstrated that xenografts had a higher CAR mRNA expression than the parental 
tumor cells (Fuxe et al. 2003).  
In conclusion, capsid modifications did not result in significant differences in 
biodistribution in mice bearing M4A4-LM3 derived xenograft tumors. 
1.3 Oncolytic potency of capsid modified replicating viruses in vitro  
Oncolytic adenoviruses convey their anticancer effect through replication and subsequent 
oncolysis of target cells. Obviously, the presence of a replicating virus within the cell is a 
prerequisite for oncolysis, and therefore transductional efficacy of the virus is of great 
importance to the cell killing ability.  
To evaluate the cell killing potency of oncolytic viruses featuring capsid modifications 
we utilized replicative viruses that have a 24 bp deletion in the viral E1A CR2, which 
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ultimately targets these viruses to cells with a defective pRb/p16 pathway (Fueyo et al. 
2000; Heise et al. 2000). The pRb/p16 pathway is mutated in a majority of human tumors, 
including advanced breast cancers (Anderson et al. 1996; Sherr 1996). We studied the cell 
killing potency in breast cancer cell lines and in vivo in murine models of breast cancer. 
In all but one cell line (MDA-MB-436) significantly enhanced cell killing was 
observed with one or more of the capsid-modified replicating viruses compared to the 
wt-capsid virus featuring the 24 bp deletion (figure 2 in studies I and II). The Ad5/3-Δ24 
displayed the most pronounced enhancement in cell killing activity, being the most 
effective in 3 (MCF-7, CAMA-1 and ZR-75-1) of the 6 cell lines tested. The 
Ad5.pK7-Δ24 was the most effective virus in the MDA-MB-435 and almost as effective 
as the Ad5/3-Δ24 in other cell lines. Ad5-Δ24RGD showed the most effective cell killing 
potency in M4A4-LM3 cell line. In the MDA-MB-436 no significant difference between 
wt capsid control virus and any of the capsid modified viruses emerged, which 
corresponds to the situation in the gene transfer efficacy study. Overall, these results 
coincide quite well with the gene transfer efficacy results, with perhaps the chimeric 
Ad5/3-Δ24 displaying a better cell killing activity than would have been expected based 
on gene transfer efficacy.  
Similar results were seen previously in renal cancer cell lines, where dramatically 
enhanced gene transfer efficacy with pK7-modified nonreplicating adenovirus did not 
convert into a dramatic enhancement in cell killing, though efficient cell killing was 
observed (Guse et al. 2007). Moreover, in the same setting the chimeric 5/3 modified virus 
displayed the most potent cell killing activity. Furthermore, the same effect was seen in 
non-small cell lung cancer (NSCLC) cell lines displaying high infectivity enhancement 
with pK7 modification, but less pronounced enhancement in cell killing, and vice versa 
with the chimeric 5/3 virus (Sarkioja et al. 2006). This suggests that in vitro, the superior 
cell killing activity of Ad5/3-Δ24 seems to be mostly related to the speed of production of 
new viral particles instead of transductional enhancement. Perhaps the concept of fiber 
chimerism is more feasible than the insertion of ligands which may interfere with the 
trimerization of the fiber in the pool of progeny virions, thus slowing down the process of 
oncolysis and subsequent infection of neighboring cells. 
1.4 Oncolytic potency of capsid modified replicating viruses in vivo 
The antitumor activity of Ad5.pK7-Δ24 was evaluated in a mammary fat pad breast cancer 
model in comparison to Ad5-Δ24E3. No significant difference existed between the viruses 
when they were injected intratumorally (figure 3a in studyI) or intravenously (figure 6a 
in study I). These results suggest that the previously mentioned upregulation of CAR on 
M4A4-LM3 derived tumors hampers any advantage the pK7 modification might have in a 
different setting, and that the infectivity of cells in vitro is not the whole truth with regard 
to gene transfer and oncolysis in vivo. Furthermore, in immunohistochemical staining the 
bulk of the tumor stained less intensively for HSPG than tumor vasculature, which also 
may play a role in the less than impressive tumor efficacy of Ad5.pK7-Δ24 if the virus 
gets stuck to the vasculature and  does not have as ample choice for receptors in the tumor 
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(figue 5g and 5h in study I). Interestingly, there seemed to be some difference between 
the viruses at later time points with Ad5.pK7-Δ24 showing somewhat enhanced efficacy 
in comparison to Ad5-Δ24E3. Perhaps the polylysine modification binding to HSPG 
resulted in extended localization in the vicinity of the tumor and a subsequent re-infection 
of tumor cells. Any further speculations are not warranted, however, as the actual situation 
was not studied. 
Poly(I) injection prior to virus injection was studied as a means to enhance gene 
transfer efficacy and subsequent viral replication and survival (figures 4B and 4C in 
study II). No signal emitted from the mice given a prior Poly(I) injection compared to 
mice that did not receive poly(I) (figure 4B). Furthermore, some mice treated with poly(I) 
seemed to die due to toxic effects of the substance. Perhaps this explains why no signal 
was obtained from the livers of the mice when imaged for luciferin. In case of extensive 
liver damage there might not be viable cells to express the transgene. We concluded, that 
poly(I) may not be the optimum compound for KC depletion. Furthermore, based on our 
data, it is not clear, whether KC depletion per se leads to enhanced gene expression in 
tumors after systemic delivery of adenoviruses, and whether that enhancement of gene 
expression would result in enhanced tumor cell killing with replicating viruses.   
In the systemic treatment model of mice bearing the M4A4-LM3 cell line derived 
tumors in the lungs all replicating viruses showed significant survival benefit compared to 
no treatment (figure 5A in study II). Neither Ad5/3-Δ24 nor Ad5.pK7-Δ24 displayed 
significant survival benefit compared to Ad5-Δ24E3, the control virus with non-modified 
capsid. Ad5-Δ24RGD showed significant survival benefit compared to the control virus, 
however, which may suggest superiority of the RGD-modification as a retargeting moiety 
in this treatment model and CAR expressing tumors. Interestingly, Ad5-Δ24RGD 
previously resulted in significant survival benefit in a systemic treatment model of 
NSCLC tumors after showing less impressive cell killing enhancement in cell lines 
(Sarkioja et al. 2006).  
Upregulation and activation of αvβ integrin reportedly to contribute to metastasis in 
human breast cancer (Felding-Habermann et al. 2001). It was also suggested that integrins 
are present in a nonactivated state in MDA-MB-435, the parental cell line of M4A4-LM3, 
but in an activated state in various in vivo selected cell variants, such as M4A4-LM3. 
These differences in integrin expression and activation may in part explain why RGD-
modified virus was superior to the highly effective control virus Ad5-Δ24E3. 
The relative differences between biodistribution data and the efficacy data can in part 
be explained by different murine models. Tumors develop in different sites, with the 
mammary fat pad model resembling a subcutaneous tumor model, where the tumor is 
somewhat “external”, and the metastatic model may better represent the disease as it is 
growing in the lungs or mediastinum and thereby is “within” the animal. With regard to 
RGD-modification this difference may play a significant role, since differences may exist 
in the tumor vasculature of the two models. RGD targets αvβ integrins that are induced in 
angiogenic vessels (Brooks et al. 1994). Their inhibition has been suggested to also inhibit 
pathologic angiogenesis. The possible difference in neovascularization of the models may 
play a role if integrin expression is different and if the lung metastasis model thereby 
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presents more available receptors for RGD-modified viruses. The vasculature of the 
tumors, however, was not studied and therefore further speculation is unwarranted. 
We utilized only xenograft murine models in this study. Xenograft models allow the use 
of human cancer cells, which is important for transductional and transcriptional studies of 
adenoviruses. However, there are various limiting aspects in using xenograft murine 
models (discussed in chapter 6), that encourage the use of other models, such as syngeneic 
tumor models.  
Syngeneic tumor models allow the use of immunocompetent animals. Tumors grow in 
endogenous stroma and display the same advantages of easy monitoring and replication of 
tumors as xenograft models do. Tumors are not of human origin, which is a downside to 
using a syngeneic model. 
Syrian hamsters are an interesting alternative for murine models which are not 
permissive for adenovirus replication. Syrian hamster model is permissive for human 
adenovirus both in vitro and in vivo. Importantly, adenoviral replication occurs not only in 
hamster cell lines and in tumors, but also in normal tissues (Thomas et al. 2006).The 
permissivity for adenoviral replication allows better assessment of the safety of replicating 
vectors (Ying et al. 2009), as well as the effect of the immune system on the vector and on 
the tumor (Dhar et al. 2009).  
2 Transcriptionally and transductionally targeted oncolytic 
adenoviruses in CD44+ CD24-/LOW cell population 
Putative breast cancer stem cells have been proposed to reside in the CD44+CD24-/LOW 
cell population (Al-Hajj et al. 2003). Cancer stem cells are thought to be highly drug-
resistant and subsequently to have a central role in post-treatment relapse. The drug-
resistant phenotype is postulated to result from the presence of transporters that have a 
well-defined role in drug efflux and the maintenance of quiescence in a subset of CSCs 
resulting in evasion of most current treatment methods targeted to proliferative cells 
(Gottesman et al. 2002; Sneddon and Werb 2007; Saini and Shoemaker). Moreover, 
enhanced DNA repair machinery and a higher tolerance for mutations due to disrupted 
apoptosis machinery presumably play a role in CSC drug-resistance (Johannessen et al. 
2008).  
Adenoviruses infect both quiescent and proliferative cells. Genetically engineered 
adenoviruses also take advantage of various cancer related cellular defects to feature 
cancer specific and effective replication. These characteristics are likely to exist also in 
CSCs, making them potential targets for adenoviruses. Furthermore, adenoviruses 
themselves inhibit apoptosis through expression of E3 gene products (Wold 1993), and 
therefore the disrupted apoptosis machinery of CSCs is perhaps irrelevant to the cytolysis 
elicited by adenovirus. The mechanism by which adenoviruses actually cause cytolysis is 
still poorly understood, but autophagy, a form of programmed cell death distinct from 
apoptosis, has been proposed to play a role (Ito et al. 2006; Rajecki et al. 2009). 
Furthermore, adenoviruses express E3 derived adenoviral death protein (ADP) that 
functions late in the viral cycle to promote cell death (Tollefson et al. 1996). These 
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characteristics help to explain how replicating adenoviruses may be effective in killing 
CSCs. 
2.1 Activity of tissue specific promoters in CD44+CD24-/LOW breast cancer 
cell population 
Marker gene expression was evaluated in sorted CD44+CD24-/LOW JIMT-1 cells infected 
with nonreplicating, luciferase expressing viruses that featured the wt capsid, chimeric 5/3 
fiber, or an RGD-modification (figure 1B in study III). Virus with the chimeric fiber 
showed the highest gene transfer efficacy, and based on this result and a previous study, 
where the 5/3 fiber modified virus was shown to be effective in the context of treating 
CD44+CD24-/LOW breast cancer cells (Eriksson et al. 2007), the 5/3 fiber was chosen as 
the capsid modification for the viruses constructed for further studies.  
We evaluated various tissue specific promoters in CD44+CD24-/LOW breast cancer cell 
populations. A multidrug resistance (mdr1), human telomerase reverse transcriptase 
(hTERT), human α-lactalbumin (ala), or cyclo-oxygenase 2 (Cox-2) promoter was 
introduced into a non-replicating 5/3-chimeric adenovirus to control the expression of a 
marker gene luciferace. Sorted CD44+CD24-/LOW JIMT-1 or pleural effusion cells from 
breast cancer patients were infected and analyzed in order to evaluate the marker gene 
expression controlled by each promoter in putative breast cancer CSCs (figure 1A in 
study III). The Mdr1 promoter showed the highest activity reaching marker gene 
expression levels of nearly 18% and 6% of the highly active but nonselective 
cytomegalovirus (CMV) promoter in JIMT-1 cells and pleural effusion cells. 
Corresponding gene expression levels were 3% and 12.8% for the hTERT promoter, 5.2% 
and 7.9% for the Cox-2 promoter and only 0.4% and 1.8% for the ala promoter. In fact, 
the activity of ala promoter may be too low for successful control of adenoviruses. 
To further evaluate promoter activities, we performed RT-PCR analysis to assess the 
expression of the genes related to each promoter (figure 1A insert in study III). 
Correlation was not perfect for the assays, suggesting that the gene expression is not solely 
regulated in transcriptional level. The mRNA expression level was highest for hTERT, 
which seems logical as it is known that hTERT gene expression is tightly regulated on the 
transcriptional level (Kyo et al. 2008). 
These results suggested that mdr1, hTERT and Cox-2 promoters are active in 
CD44+CD24-/LOW breast cencer cells, and further evaluation of the promoters in 
replicating viruses is warranted. 
2.2 Oncolytic potency of TSP controlled adenoviruses in vitro 
Oncolytic, capsid modified viruses have previously been shown to be effective in killing 
CD44+CD24-/LOW breast cancer cells (Eriksson et al. 2007). In order to avoid side effects 
in normal tissues, replication of oncolytic viruses needs to be tightly regulated. Also, E1A 
protein is expressed every time an adenovirus enters a cell, even if the E1A gene is partly 
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deleted. Regardless of partial deletions in the E1A gene, the E1A protein is toxic by itself, 
and therefore its expression in normal cells should be avoided.  
Our hypothesis was that we would gain dual control over replication by introducing 
the 24 bp deletion in the E1A to target viruses to pRb/p16 defective cells and by inserting 
a tissue specific promoter (TSP) to regulate E1A transcription. Furthermore, by 
introducing a TSP in front of E1A, we would be able to diminish the E1A protein 
expression in normal cells to very low levels. In CSCs it is notable, that normal stem cells 
and some normal highly proliferative tissues also express hTERT (Yui et al. 1998), and 
therefore promoter control would not be sufficient to gain specificity. The pRb/p16 
pathway is expected to be intact in normal cells, however, and thereby additional control 
in terms of partial E1A deletion conveys additional safety to the concept of transcriptional 
regulation of oncolytic viruses in normal stem cells. The normal stem cells occupy two 
distinct “niches”, i.e. the quiescent and the activated niche (Sneddon and Werb 2007). 
These niches may be highly dynamic in nature, suggesting that stem cells from the 
quiescent niche act as a protective cell pool sustaining the balance between these niches, 
protecting the overall stem cell pool from adenoviruses. 
All TSP controlled chimeric viruses were more effective in cell killing than the Ad5 wt 
virus in CD44+CD24-/LOW cell populations of pleural effusion samples (figure 2a-c in 
study III). In 1 out of 3 samples tested, the control virus Ad5/3-Δ24 featuring the wt E1A 
promoter, was the most effective. Impressively, in 2 out of 3 samples, the mdr1, hTERT 
and Cox-2 promoter-controlled viruses displayed similar or superior oncolytic potency in 
comparison to Ad5/3-Δ24, with Ad5/3-mdr-Δ24 being most oncolytic. Ad5/3-mdr-Δ24 
was also superior to Ad5/3-mdr-E1, which had an intact E1A gene. Therefore, we 
concluded that introducing the 24 bp deletion or TSP to the viral genome did not slow 
down viral replication. 
In order to evaluate kinetics between cell killing by TSP controlled viruses, sorted 
JIMT-1 cells were infected and we performed viability assays daily (figure 3a and b in 
study III). JIMT-1 is a cell line derived from sorted CD44+ CD24-/LOW pleural effusion 
cells (Tanner et al. 2004).  Ad5/3-mdr-Δ24 and Ad5/3-hTERT-Δgp were the most 
effective and similar in efficacy to Ad5/3-Δ24, the highly active positive control. It was 
notable that 100 % of the sorted JIMT-1 cells were killed. This result suggests, that even 
in the presence of progenitor cells in the CD44+ CD24-/LOW cell population, the TSP 
controlled replicating adenoviruses are effective in killing CSCs. 
2.3 Oncolytic potency of TSP controlled adenoviruses in vivo 
To assess antitumor activity of TSP controlled viruses, CD44+ CD24-/LOW sorted JIMT-1 
cells were injected into mammary fat pads of mice and tumors were subsequently treated 
intratumorally. Virus injections resulted in significantly smaller tumors when compared to 
mock treatments (figure 4a in study III).  Ad5/3-mdr-Δ24 and Ad5/3Cox2LΔ24 were 
most oncolytic and Ad5/3-mdr-Δ24 was superior even to  the control virus Ad5/3-Δ24. 
Interestingly, the hTERT promoter controlled virus was less effective than the control 
virus, albeit high efficacy in vitro. 
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CSCs are expected to divide in an asymmetric fashion, resulting in either two stem 
cells or one new stem cell and one progenitor cell that would subsequently proliferate to 
form heterogeneously differentiated tumor cell populations (Sagar et al. 2007). To test this 
further, CD44+CD24-/LOW mammary fat pad tumors were established and treated with 
Ad5/3-mdr-Δ24 (active in CD44+ CD24-/LOW cells in vitro) or Ad5/3-ala-Δ24 (not active 
in CD44+CD24-/LOW cells in vitro) and subsequently analyzed for CD44 and CD24 
expression with fluorescence activated cell sorting (FACS) (figure 3b and c in study III). 
Importantly, Ad5/3-mdr-Δ24 reduced tumor size and the total number of 
CD44+CD24-/LOW cells. The mean proportion of the CD44+ CD24-/LOW cells was 2.6% in 
the Ad5/3-mdr-Δ24 treated tumors that were smaller in volume than the mock treated 
tumors showing a proportion of 3.1% of CD44+CD24-/LOW cells. Ad5/3-ala-Δ24 neither 
reduced tumor size nor the proportion of CD44+CD24-/LOW cells. If the viruses were only 
able to kill fast dividing differentiated progenitor cells, the proportion of CD44+CD24-/LOW 
cells in a smaller tumor would be higher instead of similar or smaller than in a bigger 
tumor. Furthermore, this result is in accordance with the in vitro data, where the ala 
promoter controlled virus was not effective in cell killing, whereas the mdr1 promoter 
controlled virus was highly effective (figures 2a-c and 3 a and b in study III). The 
JIMT-1 cells utilized in this thesis have the appearance of epitheloid cells with variable 
nuclear size (Tanner et al. 2004). Stromal to epithelial interactions mediate normal breast 
development and the initiation and progression of breast cancer. Epithelial cells growing 
in 2-dimensional cultures are more susceptible to cytotoxic drugs than cells grown in 3-
dimensional cultures or in vivo (dit Faute et al. 2002; Krause et al. 2010), emphasizing the 
importance of tumor microenvironment on the effectiveness of cancer therapies. Further, 
this also highlites the significance of the putative ability of adenoviruses to kill tumors 
formed by epithelial like breast CSCs. 
In conclusion, the Mdr1, Cox-2 and hTERT promoters are active in CD44+CD24-/LOW 
cell populations. More importantly, 5/3-chimeric oncolytic adenoviruses featuring dual 
control over replication in terms of TSP and 24 bp deletion in E1A are effective in killing 
this cell population. These putative breast cancer stem cells are thought to be responsible 
for tumor formation, metastasis and post-treatment relapses and therefore represent the 
cell population that needs to be most desperately eradicated within a tumor. This approach 
may be interesting in a clinical context, especially for treating breast cancer patients with 
recurrent disease. 
3 Inhibition of viral replication with pharmacological agents 
The safety of adenoviral gene therapy has been validated in clinical trials with E1B-55K 
deleted viruses, of which ONYX-015 is probably the most widely studied (Khuri et al. 
2000; Xia et al. 2004). E1B-55K deleted viruses, however, have shown somewhat 
attenuated replication compared to wt virus even in tumor cells and the studies of their 
replication specificity have given contradictory results (Goodrum and Ornelles 1998; 
Rothmann et al. 1998). A similar approach for replication control featuring a 24 bp 
deletion in the E1A that targets viral replication to pRb/p16 defective cells has resulted in 
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higher replicative potency in tumor cells (Fueyo et al. 2000; Heise et al. 2000; Kanerva et 
al. 2003). With higher replicative potency, however, increase in side effects is also 
possible, especially in immunosuppressed patients (Kojaoghlanian et al. 2003). 
Our hypothesis was that the pharmacological agents apigenin and chlorpromazine 
could be used to inhibit viral replication in case of severe side effects. The antipsychotic 
agent chlorpromazine is suggested to inhibit the formation of chlatrin-coated pits which 
are needed for virus trafficking (Wang et al. 1993; Dimitrov 2004). Apigenin is a natural 
bioflavonoid that mediates cell cycle arrest to G2/M, thereby inhibiting S-phase induction 
required for adenoviral DNA replication (Sato et al. 1994). 
3.1 Inhibition of replication in vitro 
Ad5 wt and Ad5/3-Δ24 were used to study the effect of apigenin and chlorpromazine on 
viral replication in fresh human liver samples. The wt virus displayed replication over 48 
hours (figure 1A in study IV). Interestingly, adding chlorpromazine reduced replication 
8-fold. Ad5/3-Δ24 did not replicate productively in the liver samples (figure 1B in study 
IV), which is of utmost importance as Ad5/3-Δ24 is in development for human trials. 
Nevertheless, the marginal replication was even further attenuated by chlorpromazine at 
later time points. Furthermore, lower liver aspartate transaminase (AST) levels were 
measured, suggesting reduced hepatocyte damage in chlorpromazine treated liver samples 
(figure 1E in study IV). In non-malignant E1-transformed 293 cells both viruses 
replicated effectively and chlorpromazine reduced replication up to 1960 fold at the latest 
time point (48 h) (figures 1C and D in study IV). 
The effect of apigenin and chlorpromazine on viral replication in cancer cells was 
studied next. Apigenin reduced replication 100 fold in adenocarcinoma Hey cells (figures 
2A and B in study IV), but in OV-4 cells the effect was less pronounced (figures 2C and 
D in study IV). Furthermore, the close association of cell killing to replication was 
corroborated in a longitudinal assay (MTS), where apigenin reduced Ad5/3-Δ24 activity, 
albeit not statistically significantly (figure 2E in study IV). Chlorpromazine did not 
reduce replication significantly in Hey or OV-4 cell lines. This result may reflect the 
genetic heterogeneity between these cell lines. Differences in the activity of alternative 
entry mechanisms, such as caveolae, might explain the cell line specific differences in the 
results. Caveolin-1-deficient MDCK cells that lack caveolae display significantly reduced 
uptake of adenoviruses (Manninen et al. 2005). Importantly, caveolae have been suggested 
as an alternative entry route for a chimeric Ad5/F35 vector (Drouin et al. 2010), 
corroborating the possibility that cell line specific differences in alternative entry 
mechanisms for adenoviruses may effect our results. 
Previously chlorpromazine has been shown to reduce oncolytic adenovirus DNA copy 
numbers in 3 to 4 orders of magnitude and also result in as high as a 4 log reduction in 
transgene expression in various cancer cell lines (Carette et al. 2005). The chlorpromazine 
levels used by Carette et al., however, were 8 fold higher than the concentration we 
utilized. 
 
 
 
 
62
Apigenin inhibited viral replication in cancer cells, but had a less pronounced effect in 
normal cells. The opposite was true for chlorpromazine. Apigenin induces G2/M phase 
cell cycle arrest and reduces the levels of cyclins (Ujiki et al. 2006; Meeran and Katiyar 
2008). A cell arrested in G2/M will not go into mitosis and subsequently S-phase will not 
be induced either. S-phase induction is critical for adenoviral replication. Hey cells 
proliferate rapidly in vitro, and thus the effect of cell cycle arresting apigenin may be more 
clearly seen.  
3.2 Inhibition of replication and toxicity in vivo 
The use of chlorpromazine and apigenin were further studied in vivo in a subcutaneous 
ovarian cancer model. Human xenografts were used because adenoviruses do not replicate 
productively in mouse tissue. Both substances were found to reduce the antitumor efficacy 
of Ad5/3-Δ24 by inhibiting replication, with chlorpromazine displaying a 36 fold 
reduction and apigenin an 11 fold reduction in the production of new viruses (figures 3A 
and B in study IV). Recently, chlorpromazine has been shown to significantly inhibit 
viral replication in an immunocompetent syrian hamster model, which allows productive 
replication of adenoviruses (Diaconu et al. 2010). Replication was inhibited in tumors 
derived from hamster cell lines as well as in hamster livers, but the effect was significant 
only in the 24 hours post viral injections, which may suggest that chlorpromazine is 
merely slowing down the replication instead of truly inhibiting it. 
To assess the general toxicity of the treatments and to follow the overall health of the 
mice, their body weight was followed (figure 4A in study IV). No weight loss occurred in 
treated mice and the lowest body weights were seen in mock treated mice. Furthermore, 
the effects of chlorpromazine and apigenin were evaluated with regard to liver toxicity in a 
mouse model, where a combination therapy of Ad5/3-Δ24 and gemcitabine was 
previously shown to cause treatment-related toxicity (Raki et al. 2005). In that study mice 
died due to fulminant liver necrosis caused by persistant viral replication and subsequent 
sustained liver damage that was aggravated by gemcitabine, a deoxycytidine analog used 
to treat solid tumors (Fowler and Van Le 2003). When this combination treatment was 
repeated here, mice succumbed to liver necrosis, foamy degeneration, and steatosis, and 
the surviving hepatocytes displayed large nuclei (figure 4B in study IV). Analysis of 
evaluable livers in a blinded manner revealed that apigenin and chlorpromazine reduced 
liver toxicity, as toxicity was more frequently seen in PBS treated mice (figure 4C and D 
in study IV). 
A discrepancy between the effect of chlorpromazine in Hey cells in vitro and in Hey 
cell derived tumors exists. Ad5/3-Δ24 is a very potent virus in cell killing in vitro, and 
thereby the speed of its replication may become counteractive to packaging new virions. 
The cells might be lysed before the maximum number of progeny virions is produced and 
slowing the speed of replication may not be seen as reduction of in vitro virion production. 
In tumors, the rapid replication and viral release might actually improve tumor penetration 
and viral dissemination, and in this setting the effect of chlorpromazine may be more 
easily seen. As previously mentioned, the results in vitro do not always predict results in 
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vivo. Although the subcutaneous tumor model is constrained as a representation of the 
disease, it is still more truthful than any setting in vitro, and therefore we feel that the 
results in vivo give a better interpretation of the effect of the drugs. 
In this study, chlorpromazine and apigenin were delivered to cells and animals before 
any toxic events were evident. If chlorpromazine and apigenin were used in patients, the 
drugs would be delivered only after replication-associated toxicities were encountered. 
This might effect the outcome of the use of these compounds, i.e. they might not have 
strong enough effect in case viral replication had already proceeded to such levels that 
toxic effects were indeed encountered. Thus the timing of drug delivery should be looked 
at more carefully in case the use of these compounds as a safety switch was contemplated 
further. 
4 Noninvasively imagable murine models of breast cancer 
It is generally accepted that the tissue environment in which malignant cells reside 
affects tumor growth and response to therapy (Mueller and Fusenig 2004). Many proteins 
that cells express, both in vitro and in vivo, are pro survival only in the tissue context. For 
example, transforming growth factor β (TGFβ) expression has been shown to protect 
malignant cells from cytotoxic therapies in mice xenografts, but not in vitro (Teicher et al. 
1997). Various physical barriers to adenoviral cancer therapy exist in live animals, which 
hinder the target tissue transduction, tumor penetration, and viral replication. Interactions 
between tumor and matrix cells, signaling between cells residing in different niches within 
the tumor, and the formation of central hypoxia within the tumor are poorly reflected by in 
vitro 2-dimensional studies (Fischbach et al. 2007), and undoubtedly affect the gene 
transfer efficacy and spread of adenoviruses in vivo. Therefore, any results obtained in 
vitro have to be considered preliminary and further studies need to be conducted in vivo in 
order to have a better view on efficacy as well as treatment safety (comparison between 
most in vitro and in vivo models is represented in table 4).  
We developed two murine models of breast cancer that featured green fluorescent 
protein (GFP) expressing M4A4-LM3 metastatic breast cancer cells inoculated either in 
the left lung or in mediastinum to represent disseminated disease or orthotopically in the 
mammary fat pad (see figure 6 for a schematic presentation of the models). The tumor 
growth was followed by measuring with a caliber and by imaging the GFP expression 
with Xenogen IVIS 100 imaging system that can detect the light emitted by GFP 
excitation. 
Tumor growth in the orthotopic model was easily followed by fluorescence imaging, 
and the results were well in accordance with the physical measurements (figures 3A and 
B in study I). A significant correlation emerged between the photon emission and tumor 
size in the orthotopic model (figure 3C in study I). In the systemic treatment model with 
the tumor growing in lungs, however, no significant differences existed between treatment 
groups in mean fluorescence values over time, although a significant difference in survival 
between different treatment regimes occurred (figure2 5A and B in study II). GFP is a 
surface weighted molecule, i.e. the deeper the signal is emitted from, the weaker it is and 
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the more background signals from autofluorescing particles there will be (Hoffman 2002). 
Therefore, GFP may not be the optimum choice for deep-tissue imaging, although it is 
sufficient for imaging objects near the surface (figures 3A, B and D in study II).  
Table 4. Comparison between in vitro and in vivo models used in this study. 
Model Study objectives Advantages Disadvantages 
In vitro cancer cell 
lines 
 
 
 
 
* Viral gene transfer efficacy 
* Viral cell killing potential 
* Promoter activity 
* Receptor expression  
* The effect of pharmaceutical 
agents on viral replication 
 
* Easy production and 
maintenance of study material 
* Various different cell lines 
and cancer types available 
* Various available study 
methods  
 
* 2-dimensional system 
* selection of characters that promote 
survival in vitro 
* Lack of host surroundings and 
interactions such as immune system 
and blood circulation 
In vitro patient 
tissue samples 
* Viral gene transfer efficacy 
* Viral cell killing potential 
 
* Fresh samples without prior 
in vitro cultivation 
* 3-dimensional structure 
* Lack of host surroundings and 
interactions 
* Difficulty of maintenance 
In vivo orthotopic 
mfp model 
 
 
 
 
 
 
 
 
* Viral gene transfer efficacy 
* Viral cell killing potential after 
local and systemic injections, 
effect on survival 
* non-invasive imaging of tumor 
progression 
 
 
 
* Tumors with vasculature, 
blood flow and naturally 
occurring barriers such as 
stromal cells 
* Tumors easy to replicate 
* Tumors easy to measure and 
image 
* Human tumors 
* Systemic and local delivery 
possible 
* Immunocompromised mice 
* Mouse tissue non-permissive for 
viral replication 
* Tumor initiation usually requires a 
considerable number of cells (CSCs 
can be an exception) 
* Only some cancer cell lines form 
tumors 
 
In vivo lung model 
 
 
 
 
 
 
 
 
* Viral cell killing potential after 
systemic injections, effect on 
survival 
* non-invasive imaging of tumor 
progression 
 
 
 
 
* Tumors with vasculature, 
blood flow and naturally 
occurring barriers such as 
stromal cells 
* Human tumors 
* Systemic and local delivery 
possible 
* Better resemblance of 
disseminated disease 
* Disadvantages as above 
* Difficulty of tumor inoculation 
* Physical tumor measurements 
impossible 
* Imaging with GFP difficult 
 
 
 
 
In vivo orthotopic 
ovarian cancer 
model 
* The effect of pharmaceutical 
agents on viral replication 
 
* Advantages as in lung model 
 
 
* Disadvantages as in mfp model 
* Physical tumor measurements 
impossible 
 
Importantly, murine models suffer from various drawbacks. Mouse tissues are not 
permissive for adenoviral replication (Ginsberg et al. 1991), preventing reliable 
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assessment of replication related toxicity in vivo. Mice used in xenograft models are 
immunocompromised, and therefore studies assessing the effect of immune defence 
mechanisms on safety and efficacy of adenoviral vectors are impossible. In addition, 
biodistribution studies that would span a longer period than just a few days and would 
give a better view on the behavior of replicating agent after systemic delivery cannot be 
performed. Therefore, permissive immunocompetent animal models, such as the Syrian 
hamster model (Thomas et al. 2006), might be a superior model for preclinical in vivo 
studies with replicating adenoviruses, though immunocompetent models do not permit the 
use of human tissue. 
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SUMMARY AND CONCLUSIONS 
We evaluated various genetic modifications for controlling transduction and transcription 
of replicating adenoviruses with the overall goal being improvement of efficacy and safety 
of oncolytic virotherapy. With this goal in mind, we studied various capsid modified 
adenoviruses for their gene transfer potential in vitro and saw dramatic improvements 
compared to viruses utilizing the primary Ad5 receptor, CAR. Improved gene transfer 
efficacy translated into enhanced cell killing potential in vitro. As predicted based on 
literature, the situation in vivo proved to be much more complicated. Capsid modifications 
did not significantly change the viral biodistribution profile after intravenous delivery, 
though a trend towards less liver transduction was seen. Clearly, our results with xenograft 
murine models show that the use of permissive and immunocompetent animal models is 
recommendable for preclinical studies with replicating adenoviruses. Nevertheless, capsid 
modified oncolytic viruses showed efficient antitumor activity, and the treatment with 
Ad5-Δ24RGD resulted in significant survival benefit compared to the positive control 
virus in a highly aggressive model of disseminated disease.  
The 5/3 serotype chimeric capsid modification proved to be efficient in gene transfer in 
putative CSCs. Furthermore, various TSPs were successfully utilized in this context with 
Mdr1, hTERT and Cox-2 promoter controlled viruses showing even more efficient cell 
killing of CD44+ CD24-/LOW breast cancer cell populations in vitro than the highly active 
positive control virus  Ad5/3-Δ24. TSP controlled viruses were able to kill all sorted 
pleural effusion cells from breast cancer patients as well as sorted pleural effusion derived 
JIMT-1 cells. More importantly, TSP controlled viruses were able to reduce the size of 
tumors derived from CD44+CD24-/LOW cells, as well as the total number of 
CD44+CD24-/LOW cells. This result is encouraging, as the putative CSCs are thought to be 
responsible for post-treatment relapses due to various characteristics that make them 
insensitive to conventional therapies. 
When highly potent oncolytic adenoviruses are used in patients, it is beneficial to have 
an additional safety switch in case of replication related adverse effects. An antipsychotic 
chlorpromazine and a natural bioflavonoid apigenin were evaluated for their ability to 
inhibit viral replication in vitro and in vivo. Both substances inhibited replication of 
Ad5/3-Δ24 in vitro, but had different activities in cancer and normal cells, probably 
reflecting their different mechanisms of action. Furthermore, both substances inhibited 
viral replication in vivo and decreased treatment related toxicity in a murine ovarian 
cancer model. 
In conclusion, various capsid modifications can be used to gain expanded tropism of 
oncolytic adenoviruses and to circumvent their dependence on CAR. Furthermore, TSPs 
and short genomic deletion can be utilized to gain efficient viral replication in target cells, 
and oncolytic adenoviruses featuring all these genetic modifications are able to kill 
putative CSCs. An additional safety switch is achieved with pharmacologic inhibition of 
replication. Overall, oncolytic adenoviruses represent a powerful addition to the treatment 
regime for cancer and may prove to be beneficial in the treatment of relapsed disease. 
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